Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,6.5154290199279785,6.5154290199279785,6.02282190322876,6.0507049560546875,10490,0.0,0.0,,,,,,,,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-06-28,6.0507049560546875,6.3667168617248535,6.0507049560546875,6.2644782066345215,10999,0.0,0.0,,,,,,,100.0,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-06-29,6.2644782066345215,6.496840000152588,5.967054843902588,6.292360782623291,7953,0.0,0.0,,,,,,,100.0,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-06-30,6.292360782623291,6.292360782623291,5.994937896728516,6.143650054931641,18938,0.0,0.0,,,,,,,58.56792625599009,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-01,6.320244789123535,6.320244789123535,5.855521202087402,6.2644782066345215,59253,0.0,0.0,,,,,,,69.59186837393635,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-04,6.273773193359375,6.506134033203125,6.273773193359375,6.394600868225098,25940,0.0,0.0,,,,,,,76.76252186580322,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-05,6.46895694732666,6.46895694732666,6.032115936279297,6.338833808898926,72179,0.0,0.0,,,,,,,69.2279283872879,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-06,6.459661960601807,6.459661960601807,5.939170837402344,6.134355068206787,14189,0.0,0.0,,,,,,,49.89098676865136,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-07,6.032115936279297,6.496840000152588,5.929876804351807,6.496840000152588,19499,0.0,0.0,,,,,,,67.31848665841133,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-08,6.496840000152588,6.859324932098389,6.245889186859131,6.506134033203125,17650,0.0,0.0,6.2886435985565186,,,3.458463359197661,,,67.62935006016872,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-11,7.128864765167236,7.128864765167236,6.22730016708374,6.310949802398682,20033,0.0,0.0,6.314668083190918,,,-0.05888323413441815,,,55.65625081598649,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-12,6.506134033203125,6.599079132080078,6.143650054931641,6.5804901123046875,21139,0.0,0.0,6.346269273757935,,,3.6906854790304067,,,64.89821446980932,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-13,6.5804901123046875,6.5804901123046875,6.162239074707031,6.506134033203125,7331,0.0,0.0,6.367646598815918,,,2.1748605585768344,,,61.1142112366605,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-14,6.320244789123535,6.506134033203125,6.134355068206787,6.292360782623291,17781,0.0,0.0,6.382517671585083,,,-1.4125599583244304,,,51.76861780141155,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-15,6.236595153808594,6.905797004699707,6.190122127532959,6.719906806945801,29347,0.0,0.0,6.428060531616211,,,4.540191771595075,,,63.71850988242953,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-18,6.143650054931641,6.589785099029541,6.059998989105225,6.245889186859131,33937,0.0,0.0,6.413189363479614,,,-2.608689173801524,,,49.17226782615231,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-19,6.245889186859131,6.46895694732666,6.059998989105225,6.273773193359375,13645,0.0,0.0,6.406683301925659,,,-2.07455406023168,,,49.89686308825606,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-20,6.506134033203125,6.710612773895264,6.413189888000488,6.413189888000488,11298,0.0,0.0,6.434566783905029,,,-0.33221966019548504,,,53.468643572771896,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-21,6.413189888000488,6.413189888000488,6.152944087982178,6.403894901275635,24651,0.0,0.0,6.425272274017334,,,-0.3327076554894858,,,53.19636062779937,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-22,6.403894901275635,6.636257171630859,6.236595153808594,6.561901092529297,11504,0.0,0.0,6.4308489799499515,,,2.0378664308233416,,,57.18754187635859,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-25,6.561901092529297,6.784968852996826,6.4503679275512695,6.543312072753906,13881,0.0,0.0,6.454085206985473,,,1.382486640738175,,,56.57628560795862,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-26,6.543312072753906,6.719906806945801,6.441072940826416,6.710612773895264,10937,0.0,0.0,6.467097473144531,,,3.7654496744785644,,,60.652567846533465,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-27,6.710612773895264,6.775673866271973,6.3667168617248535,6.506134033203125,11198,0.0,0.0,6.467097473144531,,,0.6036179324758595,,,53.982566936915006,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-28,6.506134033203125,6.617668151855469,6.273773193359375,6.617668151855469,17044,0.0,0.0,6.499628210067749,,,1.8161029827041288,,,56.77483809745145,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-07-29,6.506134033203125,6.5154290199279785,6.329538822174072,6.431778907775879,23000,0.0,0.0,6.470815420150757,,,-0.6032703738282255,,,51.198794718027955,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-01,6.431778907775879,7.138158798217773,6.320244789123535,6.5154290199279785,34916,0.0,0.0,6.497769403457641,,,0.2717796735128816,,,53.415990552860336,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-02,6.5804901123046875,6.877913951873779,6.5154290199279785,6.599079132080078,34209,0.0,0.0,6.530299997329712,,,1.0532308588960824,,,55.58893859502615,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-03,6.608374118804932,6.859324932098389,6.413189888000488,6.524723052978516,16502,0.0,0.0,6.541453313827515,,,-0.25575755182161564,,,53.21284474555043,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-04,6.738495826721191,6.747790813446045,6.496840000152588,6.496840000152588,17127,0.0,0.0,6.55074782371521,,,-0.8229262522892968,,,52.309886822880244,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-05,6.599079132080078,6.682730197906494,6.320244789123535,6.682730197906494,6702,0.0,0.0,6.5628307342529295,,,1.826947372385846,,,57.48897668679722,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-08,6.682730197906494,6.784968852996826,6.273773193359375,6.626963138580322,106527,0.0,0.0,6.571195840835571,,,0.8486628476082642,,,55.54030232588788,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-09,6.506134033203125,6.534018039703369,6.348127841949463,6.376011848449707,34358,0.0,0.0,6.5377357482910154,,,-2.473698939018506,,,47.70408247389838,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-10,6.487545967102051,6.589785099029541,6.292360782623291,6.496840000152588,6190,0.0,0.0,6.536806344985962,,,-0.6114047552292885,,,51.269134562840215,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-11,6.543312072753906,6.55260705947876,6.320244789123535,6.55260705947876,16931,0.0,0.0,6.530300235748291,,,0.34158955829253723,,,52.86620758202396,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-12,6.506134033203125,6.970858097076416,6.506134033203125,6.970858097076416,91984,0.0,0.0,6.584208154678345,,,5.872383334711868,,,62.73143831117489,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-15,7.08239221572876,7.85383415222168,6.701319217681885,6.757084846496582,24315,0.0,0.0,6.608373737335205,,,2.2503435046539053,,,56.250976633837745,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-16,6.757084846496582,7.333343029022217,6.617668151855469,7.249692916870117,14061,0.0,0.0,6.673435115814209,,,8.635100080471824,,,65.17800958911775,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-17,7.249692916870117,7.249692916870117,6.524723052978516,6.524723052978516,41955,0.0,0.0,6.673435115814209,,,-2.228418501938933,,,49.250370891317445,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-18,6.636257171630859,6.65484619140625,6.273773193359375,6.3667168617248535,76405,0.0,0.0,6.6604228019714355,,,-4.409719157162924,,,46.57873758179775,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-19,6.348127841949463,6.357422828674316,6.004232883453369,6.152944087982178,20611,0.0,0.0,6.607444190979004,6.472441875934601,,-6.878606763222388,2.085801891035277,,43.16695221708415,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-22,6.106472015380859,6.106472015380859,5.911287784576416,6.106472015380859,37917,0.0,0.0,6.555395078659058,6.473836052417755,,-6.848146570748382,1.2598253273782452,,42.439196750168485,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-23,6.106472015380859,6.357422828674316,6.004232883453369,6.04141092300415,6007,0.0,0.0,6.521934986114502,6.4682593703269955,,-7.367814370020696,0.8298309129924849,,41.38720063838006,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-24,6.04141092300415,6.329538822174072,5.790460109710693,6.22730016708374,8838,0.0,0.0,6.494981002807617,6.466632854938507,,-4.121349017159026,0.4383757127553777,,45.54089976233917,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-25,6.218006134033203,6.5154290199279785,5.669631004333496,6.5154290199279785,51711,0.0,0.0,6.491263198852539,6.475927329063415,,0.3722822559361239,0.23681349418943637,,51.30159002201417,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-26,6.599079132080078,6.775673866271973,5.790460109710693,5.967054843902588,37750,0.0,0.0,6.390882873535157,6.468491744995117,,-6.6317602437630905,-1.1997985700454712,,42.160729055787,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-29,6.245889186859131,6.245889186859131,5.855521202087402,5.883403778076172,15904,0.0,0.0,6.303514766693115,6.455711817741394,,-6.6647101524494,-2.3575564607765678,,40.96174369439855,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-30,5.883403778076172,5.883403778076172,5.743987083435059,5.883403778076172,21853,0.0,0.0,6.166885852813721,6.4443260669708256,,-4.59684322855119,-4.305185853010638,,40.96174369439854,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-08-31,5.771871089935303,5.929876804351807,5.669631004333496,5.716104030609131,34996,0.0,0.0,6.086023950576783,6.433869791030884,,-6.0781870556489315,-5.406479331288532,,38.42699249395147,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-01,5.716104030609131,6.320244789123535,5.576686859130859,6.218006134033203,61087,0.0,0.0,6.071152877807617,6.426898944377899,,2.4188693511967143,-5.53526778076198,,48.68591805843664,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-02,5.604569911956787,6.032115936279297,5.5859808921813965,5.809049129486084,14576,0.0,0.0,6.036763381958008,6.409471821784973,,-3.7721248633413476,-5.814963388405533,,42.47584315023333,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-05,5.920581817626953,5.920581817626953,5.111962795257568,5.706809043884277,38781,0.0,0.0,5.99679708480835,6.394368302822113,,-4.835715413127739,-6.217521406114472,,41.06558152350496,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-06,5.948465824127197,5.948465824127197,5.4837422370910645,5.67892599105835,20595,0.0,0.0,5.96054859161377,6.371829199790954,,-4.724776523953697,-6.454670947405148,,40.66900678441339,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-07,5.623158931732178,5.623158931732178,5.297852039337158,5.511624813079834,50986,0.0,0.0,5.888981056213379,6.346966469287873,,-6.407835914761552,-7.21581585928686,,38.280284881091994,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-08,5.511624813079834,5.530213832855225,5.446564197540283,5.5209197998046875,3402,0.0,0.0,5.7895301342010494,6.327680444717407,,-4.639587810581972,-8.504701133661484,,38.49642572333099,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-09,5.5209197998046875,6.283067226409912,5.390797138214111,5.9019927978515625,85765,0.0,0.0,5.783023929595947,6.307232594490051,,2.05720864558013,-8.311230908973432,,46.73248477177248,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-12,5.948465824127197,5.9856438636779785,5.623158931732178,5.920581817626953,8845,0.0,0.0,5.786741733551025,6.299099910259247,,2.3128746752241343,-8.133831563359575,,47.104593665218935,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-13,5.9856438636779785,6.236595153808594,5.660336971282959,5.688220024108887,63718,0.0,0.0,5.767223358154297,6.284461081027985,,-1.3698677706613716,-8.230422882801596,,43.05574424156099,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-14,6.097177028656006,6.097177028656006,5.69751501083374,5.855521202087402,5114,0.0,0.0,5.781165075302124,6.270519363880157,,1.286178924434056,-7.804047163889528,,46.61382754044928,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-15,6.12506103515625,6.12506103515625,5.576686859130859,5.576686859130859,4292,0.0,0.0,5.71703314781189,6.249839162826538,,-2.454879743608724,-8.525115625114463,,41.913266990034415,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-16,5.576686859130859,5.7346930503845215,5.4837422370910645,5.725398063659668,18701,0.0,0.0,5.708668041229248,6.228926587104797,,0.29306350114584034,-8.352298563810258,,45.093374145717746,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-19,5.576686859130859,5.716104030609131,5.25137996673584,5.390797138214111,96485,0.0,0.0,5.677066850662231,6.2001137137413025,,-5.042563703732439,-8.436085001470913,,39.81200007288777,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-20,5.195612907409668,5.2699689865112305,5.065489768981934,5.065489768981934,26597,0.0,0.0,5.6157232284545895,6.15898563861847,,-9.798087211361315,-8.820647457878145,,35.46325242743366,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-21,5.056196212768555,5.316441059112549,4.888895034790039,5.158434867858887,32041,0.0,0.0,5.580404233932495,6.125293159484864,,-7.561627229578814,-8.895719949479012,,37.56179552018458,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-22,5.362914085388184,5.362914085388184,4.963251113891602,4.963251113891602,15617,0.0,0.0,5.524637365341187,6.083932733535766,,-10.161504082990895,-9.192990663944055,,34.98878514934765,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-23,4.972546100616455,5.074785232543945,4.712299823760986,4.879601001739502,28088,0.0,0.0,5.42239818572998,6.045128285884857,,-10.010278946665093,-10.3013545900908,,33.916491683601095,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-26,5.084078788757324,5.084078788757324,4.6472392082214355,4.777360916137695,12958,0.0,0.0,5.308076095581055,6.0016765832901005,,-9.998258688965992,-11.556778811443651,,32.60138726507428,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-27,4.777360916137695,4.90748405456543,4.693710803985596,4.795949935913086,8284,0.0,0.0,5.218849086761475,5.9565983533859255,,-8.103302927864819,-12.385412325225683,,33.109237234963985,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-28,4.7401838302612305,4.92607307434082,4.684416770935059,4.7401838302612305,18145,0.0,0.0,5.107315349578857,5.911984872817993,,-7.1883464048856895,-13.610818372334302,,32.322397025789584,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-29,4.7401838302612305,5.00972318649292,4.6472392082214355,4.7401838302612305,38389,0.0,0.0,5.023665046691894,5.868068468570709,,-5.642916352819688,-14.389801795964512,,32.322397025789584,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-09-30,4.7401838302612305,4.7401838302612305,4.461349010467529,4.730888843536377,36275,0.0,0.0,4.924214124679565,5.819272434711456,,-3.9260128875035214,-15.380931552421318,,32.17458893750822,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-03,4.72159481048584,5.3350300788879395,4.6565327644348145,4.92607307434082,20340,0.0,0.0,4.877741718292237,5.776750183105468,,0.9908551710996517,-15.562529732416822,,38.53125799375887,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-04,4.92607307434082,4.92607307434082,4.693710803985596,4.82383394241333,54071,0.0,0.0,4.853576135635376,5.737945735454559,,-0.6127892587009467,-15.412651854734271,,36.59646962301445,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-05,4.82383394241333,4.82383394241333,4.72159481048584,4.814538955688477,9849,0.0,0.0,4.819186544418335,5.695888209342956,,-0.09643927843467609,-15.391834121438153,,36.417431344272636,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-06,4.814538955688477,5.325736045837402,4.703005790710449,4.833127975463867,24012,0.0,0.0,4.806174230575562,5.652901232242584,,0.5608149766363683,-14.978627201860986,,37.08038800249314,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-07,4.833127975463867,4.833127975463867,4.507822036743164,4.777360916137695,47082,0.0,0.0,4.795950222015381,5.598063802719116,,-0.38760422892533003,-14.328410839371447,,35.871994099456344,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-10,4.777360916137695,4.777360916137695,4.554294109344482,4.7401838302612305,22985,0.0,0.0,4.792232513427734,5.547641277313232,,-1.0861051299298312,-13.6167557728489,,35.05191030300492,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-11,4.540351867675781,4.730888843536377,4.540351867675781,4.712299823760986,4259,0.0,0.0,4.783867502212525,5.484206449985504,,-1.4960213345883555,-12.770105468491813,,34.41638553085113,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-12,4.712299823760986,4.730888843536377,4.489233016967773,4.637944221496582,24391,0.0,0.0,4.773643541336059,5.437036979198456,,-2.842678106658494,-12.201378074132498,,32.71310656201521,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-13,4.637944221496582,4.637944221496582,4.368403911590576,4.605413913726807,19897,0.0,0.0,4.7601665496826175,5.3930044054985045,,-3.2509920470351816,-11.734421265643121,,31.967703580645278,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-14,4.610061168670654,4.633296966552734,4.242928981781006,4.619355201721191,16928,0.0,0.0,4.749013185501099,5.35466468334198,,-2.7302089658491058,-11.310726883142179,,32.67571537835144,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-17,4.37305212020874,4.586824893951416,4.2475762367248535,4.419524192810059,32643,0.0,0.0,4.6983582973480225,5.31249098777771,,-5.934713508234379,-11.560164371903955,,28.15304080773639,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-18,4.312637805938721,4.447406768798828,4.089570045471191,4.228987216949463,40963,0.0,0.0,4.638873624801636,5.267180395126343,,-8.835903734491149,-11.92871181906114,,24.649696079109376,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-19,4.228987216949463,4.228987216949463,3.8107359409332275,3.9780359268188477,112497,0.0,0.0,4.5552233219146725,5.210948789119721,,-12.670891289106297,-12.583609890279101,,20.951662127128046,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-20,3.894386053085327,4.610061168670654,3.7177910804748535,3.9455060958862305,80726,0.0,0.0,4.466461133956909,5.146700716018676,,-11.663709197199628,-13.217002883897603,,20.521874984058357,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-21,3.8107359409332275,3.9919779300689697,3.5319008827209473,3.9408578872680664,12761,0.0,0.0,4.382810831069946,5.096045792102814,,-10.083778671642756,-13.995850707192345,,20.457298898280413,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-24,3.9036800861358643,4.168572902679443,3.8107359409332275,4.140689849853516,24075,0.0,0.0,4.322861433029175,5.052477943897247,,-4.214143478756047,-14.440765877055567,,30.572006225313885,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-25,4.140689849853516,4.140689849853516,3.7317330837249756,3.843266010284424,22328,0.0,0.0,4.235958051681519,5.001474499702454,,-9.270442166942864,-15.305815276404525,,25.395811691082088,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-26,3.843266010284424,3.964095115661621,3.8200299739837646,3.8897390365600586,19377,0.0,0.0,4.161137533187866,4.955815374851227,,-6.522218851533325,-16.035259216798742,,27.46242649423627,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-27,3.8386189937591553,4.270812034606934,3.7642629146575928,3.815382957458496,79875,0.0,0.0,4.082134437561035,4.895749795436859,,-6.534607916095875,-16.618810026487942,,26.211344332337674,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-28,3.857208013534546,4.270812034606934,3.6062569618225098,3.880444049835205,21791,0.0,0.0,4.0082433223724365,4.847534668445587,,-3.1884110384194044,-17.31377707386832,,29.248534047781533,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-10-31,3.9036800861358643,3.9547998905181885,3.857208013534546,3.857208013534546,8136,0.0,0.0,3.9520117044448853,4.801294642686844,,-2.39887171396057,-17.688623620205338,,28.792717221151676,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-01,3.745673894882202,4.108159065246582,3.7177910804748535,4.015213966369629,51523,0.0,0.0,3.930634379386902,4.759701842069626,,2.1518049968290294,-17.41847473206908,,36.08683331930694,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-02,4.043097972869873,4.05239200592041,3.847913980484009,3.9547998905181885,18500,0.0,0.0,3.928310775756836,4.720781219005585,,0.6743131150627761,-16.786849601466596,,34.62632501816931,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-03,3.959446907043457,4.312637805938721,3.959446907043457,4.047745227813721,4474,0.0,0.0,3.938534688949585,4.6839518547058105,,2.772872336774117,-15.914278986606782,,38.734468613557596,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-04,4.256871223449707,4.256871223449707,3.829324960708618,3.8618550300598145,9837,0.0,0.0,3.9306344032287597,4.632948410511017,,-1.7498288091216891,-15.159115644130209,,34.11678306900461,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-07,3.9408578872680664,3.9455060958862305,3.7177910804748535,3.9455060958862305,16063,0.0,0.0,3.911116027832031,4.583571517467499,,0.8792904073792475,-14.670993723405696,,37.71517664243335,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-08,4.29404878616333,4.29404878616333,3.722438097000122,3.8386189937591553,24667,0.0,0.0,3.9106513261795044,4.5373314917087555,,-1.841952309533073,-13.811646045134864,,35.07874553542679,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-09,3.8386189937591553,4.131394863128662,3.8386189937591553,4.024508953094482,4560,0.0,0.0,3.9241283178329467,4.491556185483932,,2.5580365148958673,-12.633213171969915,,42.59444666433999,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-10,4.024508953094482,4.1825151443481445,3.7038490772247314,4.043097972869873,57320,0.0,0.0,3.9468998193740843,4.453216463327408,,2.4373092274494126,-11.369684095145193,,43.30131869359575,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-11,4.089570045471191,4.089570045471191,3.857208013534546,3.857208013534546,87475,0.0,0.0,3.9445762157440187,4.40651171207428,,-2.2148945141624954,-10.483019824150512,,38.23150077009257,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-14,4.122100830078125,4.122100830078125,3.7642629146575928,3.964095115661621,47414,0.0,0.0,3.955264925956726,4.370844161510467,,0.2232515361220491,-9.507985647562554,,42.40705905126561,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-15,4.084922790527344,4.084922790527344,3.7177910804748535,3.7735579013824463,22325,0.0,0.0,3.9310993194580077,4.33854586482048,,-4.007566466096871,-9.391315847696625,,37.53588793376503,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-16,4.07562780380249,4.07562780380249,3.722438097000122,3.7270851135253906,11570,0.0,0.0,3.908327841758728,4.302762120962143,,-4.637347110363674,-9.1670017564256,,36.43653804776959,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-17,3.9966249465942383,3.9966249465942383,3.6155519485473633,3.843266010284424,26869,0.0,0.0,3.8878799200057985,4.274762493371964,,-1.1475125425506494,-9.05038757044463,,41.08228765794697,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-18,3.847913980484009,4.066333770751953,3.7177910804748535,3.778204917907715,79193,0.0,0.0,3.8795149087905885,4.247227591276169,,-2.6114087267280617,-8.657710814482007,,39.347919313038844,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-21,3.778204917907715,3.9826838970184326,3.7270851135253906,3.7410271167755127,4495,0.0,0.0,3.8590670108795164,4.221319246292114,,-3.0587676703002202,-8.581493468677822,,38.35155820818251,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-22,3.7410271167755127,3.8990330696105957,3.7317330837249756,3.745673894882202,11955,0.0,0.0,3.849772500991821,4.195062345266342,,-2.704019681235707,-8.230863235301893,,38.56096573702844,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-23,3.950153112411499,3.950153112411499,3.671319007873535,3.7177910804748535,18125,0.0,0.0,3.8191007137298585,4.169502526521683,,-2.652709128376525,-8.4039237430116,,37.73272289554523,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-24,3.7177910804748535,3.7177910804748535,3.6899070739746094,3.70849609375,78397,0.0,0.0,3.785640525817871,4.143710333108902,,-2.03781715516172,-8.641284706365607,,37.44399495296325,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-25,3.8107359409332275,3.871150016784668,3.685260057449341,3.8386189937591553,53993,0.0,0.0,3.783781623840332,4.121403586864472,,1.4492741751614675,-8.191917047391115,,43.914135726091516,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-28,3.88509202003479,3.88509202003479,3.6248459815979004,3.634140968322754,58533,0.0,0.0,3.7507862091064452,4.089105284214019,,-3.1098877483470293,-8.2736699496013,,37.37265241247344,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-29,3.6527299880981445,3.6527299880981445,3.4900760650634766,3.643435001373291,36849,0.0,0.0,3.7377739191055297,4.059595310688019,,-2.5239332226603612,-7.927425443989569,,37.82599134806502,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-11-30,3.578373908996582,3.6248459815979004,3.2437729835510254,3.4017789363861084,68883,0.0,0.0,3.7052433013916017,4.02427631020546,,-8.19013328737466,-7.9277113255071185,,31.451097261685447,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-01,3.327423095703125,3.5969629287719727,2.904524087905884,3.0160579681396484,192078,0.0,0.0,3.622522497177124,3.978849560022354,,-16.741497934383215,-8.955529920644405,,24.38643753506527,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-02,3.0671770572662354,3.11365008354187,2.885935068130493,3.0253520011901855,47367,0.0,0.0,3.547237205505371,3.9350493371486666,,-14.712441657558475,-9.855330859061198,,24.824611707015805,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-05,2.7883429527282715,2.927759885787964,2.713987112045288,2.7883429527282715,61807,0.0,0.0,3.451968789100647,3.8862533152103422,,-19.224560733797137,-11.174889820227525,,21.416316196657647,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-06,2.7883429527282715,2.8441100120544434,2.6861040592193604,2.769753932952881,42302,0.0,0.0,3.354376792907715,3.8376896679401398,,-17.428658020498,-12.593849864151228,,21.170806624394203,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-07,2.611747980117798,2.83481502532959,2.546686887741089,2.6396310329437256,23291,0.0,0.0,3.246560788154602,3.7877318382263185,,-18.694544621659933,-14.287470000123626,,19.486791721978648,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-08,2.546686887741089,3.5133121013641357,2.546686887741089,2.8812880516052246,150502,0.0,0.0,3.1638399839401243,3.7446286916732787,,-8.930664438440418,-15.509914481631295,,30.537482075128324,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-09,2.885935068130493,2.950995922088623,2.648926019668579,2.941701889038086,74500,0.0,0.0,3.0741482734680177,3.7026873588562013,5.176597972710927,-4.308392850567221,-16.97521352659777,-28.472572558746627,33.01282642871233,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-12,3.0160579681396484,3.406425952911377,2.7093400955200195,2.7883429527282715,90411,0.0,0.0,2.9895684719085693,3.6619078278541566,5.149411622683207,-6.730921906325616,-18.36035715676579,-28.88686909930801,30.082251757340217,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-13,2.783695936203003,2.8812880516052246,2.4444470405578613,2.8812880516052246,95444,0.0,0.0,2.913353776931763,3.6282153487205506,5.121218371391296,-1.100646463894564,-19.702842942905132,-29.15327788034036,33.9113712031246,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-14,2.8673460483551025,2.8673460483551025,2.621042013168335,2.7232820987701416,1801,0.0,0.0,2.845504093170166,3.596846503019333,5.091476049025854,-4.295266863027322,-20.888920592481806,-29.355525423565265,30.821134538643463,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-15,2.7232820987701416,2.9695849418640137,2.621042013168335,2.79298996925354,13505,0.0,0.0,2.823197293281555,3.5680335998535155,5.063553881645203,-1.069968581363414,-20.87526044044371,-29.534992946609602,33.69195265912987,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-16,2.4165639877319336,2.4165639877319336,1.5335880517959595,1.7306309938430786,1630829,0.0,0.0,2.6937251925468444,3.5127779275178908,5.025771821538608,-35.75324615029443,-23.316382415035967,-30.10470725186094,20.04169495783883,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-19,1.7473609447479248,1.7473609447479248,1.5335880517959595,1.6525579690933228,191688,0.0,0.0,2.5801466941833495,3.450574630498886,4.986254797379176,-35.951007250137025,-25.22559369161332,-30.798269027235797,19.419026980792935,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-20,1.5800609588623047,1.5800609588623047,1.4889750480651855,1.542883038520813,54421,0.0,0.0,2.457459604740143,3.393065056204796,4.946288540959358,-37.21634180497706,-27.574049891962417,-31.40179696134966,18.547274428685654,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-21,1.5149990320205688,1.542883038520813,1.425773024559021,1.4685269594192505,45217,0.0,0.0,2.3403491973876953,3.3325347542762755,4.907406640052796,-37.25180152353227,-29.77269946293636,-32.09173401125726,17.95865661044131,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-22,1.5521769523620605,1.5782020092010498,1.414618968963623,1.5484600067138672,56329,0.0,0.0,2.2070663928985597,3.27586168050766,4.866170140107473,-29.8408053470353,-32.62638633275472,-32.680905389894356,20.866094715978562,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-23,1.5057049989700317,2.318972110748291,1.5057049989700317,1.764091968536377,152342,0.0,0.0,2.0893054008483887,3.2229528784751893,4.8266531229019165,-15.565624450114123,-35.17418716227525,-33.2259270262732,28.252851625020213,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-27,1.764091968536377,1.872836947441101,1.6190979480743408,1.8124229907989502,73891,0.0,0.0,1.9917134046554565,3.1718332529067994,4.789165399471918,-9.001817903993146,-37.206238605696946,-33.770647109900516,29.833796465175965,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-28,1.8124229907989502,1.8124229907989502,1.6098029613494873,1.6990300416946411,75640,0.0,0.0,1.8734876036643981,3.1139286547899245,4.748486565550168,-9.311914401169851,-39.83524314911481,-34.42271317810627,28.2604104320655,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-29,1.8496010303497314,1.8496010303497314,1.4926929473876953,1.5800609588623047,52240,0.0,0.0,1.7591654896736144,3.0545601814985277,4.707435956597328,-10.181221258753762,-42.40855032652882,-35.11201831184437,26.67112863747836,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2022-12-30,1.734349012374878,1.7399259805679321,1.4517970085144043,1.576343059539795,41644,0.0,0.0,1.63750079870224,2.9927751272916794,4.668135808904966,-3.734821943959611,-45.284870093661155,-35.88928750567534,26.62074484649797,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-02,1.5986499786376953,1.7882570028305054,1.5893549919128418,1.775244951248169,94227,0.0,0.0,1.641962194442749,2.940609875321388,4.626930293440819,8.11728535873225,-44.16252872498791,-36.44577097930295,33.823209263364646,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-03,1.7566560506820679,1.7566560506820679,1.5633310079574585,1.6525579690933228,45972,0.0,0.0,1.641962194442749,2.8832861721515655,4.588652533292771,0.6453117304670847,-43.05240283459328,-37.16486155288493,31.75289889808407,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-04,1.7455029487609863,1.7473609447479248,1.5242940187454224,1.5633310079574585,63982,0.0,0.0,1.6440069913864135,2.8264039725065233,4.549398848414421,-4.907277393079687,-41.8339696880461,-37.873023081025416,30.300286710756396,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-05,1.5633310079574585,1.5800609588623047,1.4871159791946411,1.5373059511184692,107514,0.0,0.0,1.6508848905563354,2.7642238974571227,4.508766482273738,-6.879882424727439,-40.27673040251823,-38.69223637274856,29.87104980373229,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-09,1.5800609588623047,1.6637109518051147,1.414618968963623,1.4313490390777588,184222,0.0,0.0,1.6391737937927247,2.69893017411232,4.467328600088755,-12.67862843476166,-39.265794665034264,-39.585143254098234,28.12421052527715,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-10,1.4313490390777588,1.4871159791946411,1.4313490390777588,1.4387849569320679,58532,0.0,0.0,1.6066430926322937,2.638469597697258,4.424635965625445,-10.447755103170437,-39.107007560954955,-40.368662683319826,28.440481869195324,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-11,1.4387849569320679,1.5558949708938599,1.4387849569320679,1.542883038520813,46655,0.0,0.0,1.57968909740448,2.5779392957687377,4.382965723673503,-2.3299558719586924,-38.722796925541296,-41.18276394805832,32.89234789722981,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-12,1.5335880517959595,1.5651899576187134,1.4871159791946411,1.4871159791946411,58797,0.0,0.0,1.55849769115448,2.5207782477140426,4.3394365837176645,-4.5801615469164885,-38.17394717017265,-41.91001068727564,31.752688987639743,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-13,1.5335880517959595,1.5335880517959595,1.414618968963623,1.4871159791946411,137056,0.0,0.0,1.5492031931877137,2.464779019355774,4.297611433267593,-4.007686936490171,-37.14636561647489,-42.64769959712867,31.752688987639743,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-16,1.4871159791946411,1.531730055809021,1.3588520288467407,1.5149990320205688,106047,0.0,0.0,1.543068790435791,2.4065723448991774,4.255089190602303,-1.8190866531163956,-35.881055323087025,-43.44249351542899,33.09687193903588,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-17,1.5800000429153442,1.600000023841858,1.4479999542236328,1.4980000257492065,98238,0.0,0.0,1.5153442978858949,2.3495672225952147,4.213974366585414,-1.144576329015516,-35.50538655318313,-44.24343818448354,32.67435151098745,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-18,1.5920000076293945,1.5959999561309814,1.3980000019073486,1.559999942779541,131782,0.0,0.0,1.5060884952545166,2.2950415432453157,4.172679124275843,3.5795670503354997,-34.3764168588938,-44.99836975498053,35.88908514033821,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-19,1.5800000429153442,1.5800000429153442,1.4500000476837158,1.5160000324249268,9811,0.0,0.0,1.5013553977012635,2.239299696683884,4.130320131778717,0.9754275867050397,-32.9542445825997,-45.78387085653014,34.62549618723814,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-20,1.5160000324249268,1.5479999780654907,1.4520000219345093,1.4520000219345093,40272,0.0,0.0,1.4928248047828674,2.182654920220375,4.088047439853351,-2.734733688612316,-31.605092909870415,-46.60886517748746,32.81566692986648,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-23,1.5520000457763672,1.5520000457763672,1.4520000219345093,1.5,62195,0.0,0.0,1.4996899008750915,2.127442517876625,4.046407106518745,0.02067754972061815,-29.507383241925893,-47.42391306971254,35.53709673839502,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-24,1.5,1.5399999618530273,1.4500000476837158,1.4500000476837158,196974,0.0,0.0,1.5008114099502563,2.067727044224739,4.002801021933555,-3.3855927486735062,-27.417334210427114,-48.34299699399191,33.99246477387216,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-25,1.4500000476837158,1.5119999647140503,1.4240000247955322,1.4600000381469727,235943,0.0,0.0,1.4925231099128724,2.0133735209703447,3.959742996096611,-2.17906654509345,-25.869537154062133,-49.1539344105144,34.60468041213828,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-26,1.4600000381469727,1.4980000257492065,1.4559999704360962,1.4639999866485596,147765,0.0,0.0,1.490211510658264,1.9588876456022262,3.9188095639149347,-1.7589130014252947,-23.925626158098297,-50.0131962614362,34.8649152185377,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-27,1.4579999446868896,1.5,1.4559999704360962,1.4600000381469727,190851,0.0,0.0,1.4874999165534972,1.910343173146248,3.876835897564888,-1.8487314251580698,-22.13441346752098,-50.72416724303008,34.71613855573705,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-30,1.4600000381469727,1.5379999876022339,1.4600000381469727,1.4639999866485596,132672,0.0,0.0,1.4824000120162963,1.8715417236089706,3.834430838624636,-1.2412321383288343,-20.792574735778608,-51.19114668188226,35.014776850672604,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-01-31,1.4700000286102295,1.503999948501587,1.4620000123977661,1.496000051498413,141457,0.0,0.0,1.482200014591217,1.8333079248666764,3.788807021578153,0.9310509223683943,-19.151605985720753,-51.6125283123275,37.47881815622051,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-01,1.5,1.5,1.4739999771118164,1.4759999513626099,81142,0.0,0.0,1.4738000154495239,1.8004993498325348,3.74479798078537,0.14926963563743614,-18.14492931715845,-51.91998716430282,36.546121001281136,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-02,1.4759999513626099,1.5499999523162842,1.4639999866485596,1.4700000286102295,492887,0.0,0.0,1.4692000150680542,1.7680055022239685,3.6966338733832043,0.054452323303184544,-16.900710251186876,-52.172555822904144,36.254635817998356,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-03,1.4700000286102295,1.6799999475479126,1.4700000286102295,1.503999948501587,195700,0.0,0.0,1.4744000077247619,1.739614725112915,3.6547945141792297,2.0075922830808004,-15.245600854001657,-52.40184589410257,39.21333252688387,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-06,1.600000023841858,1.600000023841858,1.4320000410079956,1.4320000410079956,205165,0.0,0.0,1.4676000118255614,1.7033825248479844,3.6136718740065894,-2.4257270735016343,-13.842017842907303,-52.86283358761648,35.45990419426353,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-07,1.4279999732971191,1.4880000352859497,1.4040000438690186,1.4880000352859497,60902,0.0,0.0,1.471400010585785,1.667039978504181,3.5747973402341207,1.1281789167281608,-11.735769414116982,-53.366867549616025,40.25029421969708,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-08,1.4900000095367432,1.527999997138977,1.399999976158142,1.4759999513626099,50277,0.0,0.0,1.4730000019073486,1.6342314034700394,3.5362100730339687,0.20366255610161033,-9.865885652444364,-53.78579412088166,39.572472564960215,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-09,1.5,1.5,1.4359999895095825,1.4359999895095825,21092,0.0,0.0,1.470200002193451,1.5980992019176483,3.4978316485881806,-2.3262149797880576,-8.003207784017663,-54.311717587589314,37.31663006499221,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-10,1.437999963760376,1.5800000429153442,1.434000015258789,1.5099999904632568,145324,0.0,0.0,1.4751999974250793,1.5677671492099763,3.45852081378301,2.359001701390992,-5.904394146257181,-54.669431423918,43.709654093857296,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-13,1.4980000257492065,1.5240000486373901,1.4459999799728394,1.4459999799728394,82050,0.0,0.0,1.4733999967575073,1.5340923994779587,3.4162755717833835,-1.8596455032555204,-3.9562416671319545,-55.09459447157177,39.91778418493854,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-14,1.4479999542236328,1.4900000095367432,1.440000057220459,1.4620000123977661,74189,0.0,0.0,1.4699999928474425,1.527376624941826,3.37873344818751,-0.5442163597688308,-3.7565477405789625,-54.79440303995651,41.28904697287324,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-15,1.4620000123977661,1.4620000123977661,1.3980000019073486,1.4040000438690186,105361,0.0,0.0,1.4628000020980836,1.5211626768112183,3.341405083735784,-4.0196854077610515,-3.8367148762471075,-54.4753587580433,37.911243642752474,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-16,1.4199999570846558,1.4600000381469727,1.399999976158142,1.4160000085830688,10097,0.0,0.0,1.4574000000953675,1.5179906010627746,3.304176718990008,-2.840674592396706,-3.991500403558918,-54.05843179214759,39.02273059238264,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-17,1.4700000286102295,1.4980000257492065,1.440000057220459,1.4600000381469727,14117,0.0,0.0,1.453000009059906,1.5177774280309677,3.26870918571949,0.4817638708478525,-4.267912921534108,-53.566458751916066,43.048546417219185,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-20,1.4600000381469727,1.5779999494552612,1.399999976158142,1.4800000190734863,278041,0.0,0.0,1.4578000068664552,1.5160659283399582,3.229225801428159,1.5228434697808888,-3.8432313782885625,-53.051721323746946,44.831493500403504,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-21,1.4800000190734863,1.4800000190734863,1.4119999408721924,1.4359999895095825,94474,0.0,0.0,1.4526000022888184,1.5078636288642884,3.1927837252616884,-1.1427793441470258,-3.6650281575591928,-52.77276011732677,41.73584978199108,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-22,1.4459999799728394,1.4800000190734863,1.3819999694824219,1.4800000190734863,139631,0.0,0.0,1.453000009059906,1.4995530545711517,3.1575603167215984,1.8582250409653736,-3.104461383966115,-52.509124002163375,45.76861677090139,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-23,1.4980000257492065,1.5379999876022339,1.4119999408721924,1.4880000352859497,161000,0.0,0.0,1.4582000136375428,1.4942773044109345,3.122635933756828,2.043616881752007,-2.414363831057041,-52.14692535055866,46.49376812494955,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-24,1.4880000352859497,1.5379999876022339,1.4600000381469727,1.5160000324249268,178292,0.0,0.0,1.4588000178337097,1.49267578125,3.089339060584704,3.92103193665695,-2.2694656027661924,-51.68300558866179,49.061084991851374,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-27,1.4199999570846558,1.4880000352859497,1.3919999599456787,1.4539999961853027,249081,0.0,0.0,1.459600019454956,1.4896172046661378,3.0554480622212092,-0.3836683471506479,-2.0150938856744287,-51.247176377030755,44.02395870823608,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-02-28,1.444000005722046,1.4479999542236328,1.399999976158142,1.4240000247955322,118604,0.0,0.0,1.4558000206947326,1.4808360815048218,3.0181314557790757,-2.1843656715999256,-1.6906706368639846,-50.93533521645196,41.788258615228365,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-01,1.3799999952316284,1.409999966621399,1.350000023841858,1.3980000019073486,132225,0.0,0.0,1.4552000164985657,1.4744721323251724,2.9804432739814124,-3.930732129102709,-1.3070518868481764,-50.52842826444722,39.89720227442016,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-02,1.4040000438690186,1.4600000381469727,1.3819999694824219,1.4279999732971191,203057,0.0,0.0,1.4564000129699708,1.471088856458664,2.9449414402246474,-1.9500164391606074,-0.9985014449809266,-50.046923298194834,43.096962514749634,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-03,1.4579999446868896,1.4579999446868896,1.409999966621399,1.440000057220459,11041,0.0,0.0,1.4544000148773193,1.4686562091112136,2.9081454306840895,-0.990096088391127,-0.9706964874047526,-49.498529419632966,44.37269293469753,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-06,1.4600000381469727,1.4600000381469727,1.4119999408721924,1.4420000314712524,66780,0.0,0.0,1.450600016117096,1.468922483921051,2.8736897071202594,-0.5928570626149323,-1.2473406871032577,-48.88374759872504,44.595635116449536,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-07,1.4220000505447388,1.4459999799728394,1.399999976158142,1.4459999799728394,28383,0.0,0.0,1.4516000151634216,1.4691028594970703,2.8380280564228695,-0.38578362717582515,-1.191396791620198,-48.235083294110595,45.069800739239135,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-08,1.409999966621399,1.444000005722046,1.409999966621399,1.440000057220459,55170,0.0,0.0,1.4476000189781189,1.4665307849645615,2.805104747414589,-0.525004259327434,-1.2908536377502686,-47.719214895050364,44.455211842428355,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-09,1.3600000143051147,1.4420000314712524,1.3600000143051147,1.4199999570846558,85749,0.0,0.0,1.4408000111579895,1.4648528844118118,2.7747256656487784,-1.443646162704876,-1.6419992416836025,-47.207289623376006,42.38059765573338,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-10,1.4199999570846558,1.4240000247955322,1.3619999885559082,1.4140000343322754,62293,0.0,0.0,1.4306000113487243,1.4630249857902526,2.7435220420360564,-1.1603506839622457,-2.2162966973536697,-46.67347433795376,41.7511190819469,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-13,1.4479999542236328,1.4479999542236328,1.3700000047683716,1.4320000410079956,56842,0.0,0.0,1.4284000158309937,1.4609500110149383,2.7140949497620266,0.25203200343760107,-2.2280019808023193,-46.17174277034651,44.41832881034469,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-14,1.3899999856948853,1.4500000476837158,1.350000023841858,1.440000057220459,310087,0.0,0.0,1.4300000190734863,1.4595000118017196,2.685431608557701,0.6993033575937881,-2.021239636155691,-45.65119412645955,45.61036276677206,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-15,1.440000057220459,1.4479999542236328,1.3580000400543213,1.440000057220459,77386,0.0,0.0,1.4342000246047975,1.4565000146627427,2.657620268066724,0.40440890504515,-1.5310669298626054,-45.19533011680904,45.61036276677206,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-16,1.4320000410079956,1.4320000410079956,1.350000023841858,1.409999966621399,35964,0.0,0.0,1.4324000239372254,1.4538500130176544,2.6294040183226266,-1.563812967152546,-1.4753921579507854,-44.70800215993023,41.71907980219707,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-17,1.3600000143051147,1.3899999856948853,1.3200000524520874,1.378000020980835,88979,0.0,0.0,1.426200020313263,1.4520000129938126,2.6013858199119566,-3.3796100579104573,-1.7768589841369105,-44.18359622476318,37.99540518631779,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-20,1.315999984741211,1.3480000495910645,1.315999984741211,1.3480000495910645,23528,0.0,0.0,1.4168000221252441,1.4482000142335891,2.5731176217397054,-4.856011537251219,-2.1682082446990147,-43.718079500211516,34.85451779802973,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-21,1.350000023841858,1.5099999904632568,1.2999999523162842,1.4359999895095825,172065,0.0,0.0,1.4158000230789185,1.4478500127792358,2.5456602146228153,1.4267527971030445,-2.2136263713390694,-43.12477350816592,48.34382754559418,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-22,1.399999976158142,1.399999976158142,1.2599999904632568,1.3899999856948853,37886,0.0,0.0,1.4108000159263612,1.4461000114679337,2.516192938884099,-1.4743429257631657,-2.4410480092410425,-42.52825412866545,43.29694858115259,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-23,1.4220000505447388,1.4220000505447388,1.4179999828338623,1.4179999828338623,1000,0.0,0.0,1.4106000185012817,1.4449500113725662,2.4878109892209372,0.5245969258133741,-2.3772443753023142,-41.91881868706372,46.928780391711925,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-24,1.4140000343322754,1.4140000343322754,1.3899999856948853,1.399999976158142,40238,0.0,0.0,1.4092000126838684,1.4434500098228455,2.4593564977248508,-0.6528552684444376,-2.372787204676429,-41.30781726202849,44.93620372684481,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-27,1.4199999570846558,1.440000057220459,1.3980000019073486,1.3980000019073486,17644,0.0,0.0,1.4058000087738036,1.4418000102043151,2.4307304312785467,-0.5548447017907245,-2.4968789829187212,-40.68449583502607,44.70905636486186,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-28,1.468000054359436,1.468000054359436,1.3459999561309814,1.4279999732971191,22883,0.0,0.0,1.4046000003814698,1.4401000082492827,2.4028190900882085,1.665952791491828,-2.465107122037308,-40.06623244380766,48.883099648506374,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-29,1.4539999961853027,1.4539999961853027,1.3799999952316284,1.4299999475479126,123278,0.0,0.0,1.403599989414215,1.4389500081539155,2.375234224398931,1.8808747743518748,-2.4566537085643687,-39.41860582115637,49.158654605469295,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-30,1.4279999732971191,1.4279999732971191,1.3899999856948853,1.4279999732971191,15499,0.0,0.0,1.405399990081787,1.4379000067710876,2.3478650589783987,1.6080819250622644,-2.260241778722973,-38.757127405067074,48.87491860187127,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-03-31,1.3919999599456787,1.4579999446868896,1.3899999856948853,1.4479999542236328,183291,0.0,0.0,1.412399983406067,1.4365000069141387,2.3212821900844576,2.5205303905282466,-1.6776904554176038,-38.11609751497412,51.86683036409528,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-03,1.475000023841858,1.475000023841858,1.3650000095367432,1.3949999809265137,37795,0.0,0.0,1.4170999765396117,1.4355750054121017,2.294528740644455,-1.5595226856938913,-1.2869427792236088,-37.434864947087235,44.44415927547909,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-04,1.3849999904632568,1.4450000524520874,1.3849999904632568,1.4299999475479126,603957,0.0,0.0,1.4164999723434448,1.4341250032186508,2.267950780193011,0.9530515685174025,-1.228974520048779,-36.76560286301269,49.57612115125457,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-05,1.4299999475479126,1.434999942779541,1.3600000143051147,1.4199999570846558,98581,0.0,0.0,1.419499969482422,1.432725003361702,2.2429547448952993,0.03522279767403612,-0.9230685475753739,-36.12332096211859,48.20596177083946,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-06,1.4199999570846558,1.4199999570846558,1.3049999475479126,1.3700000047683716,52103,0.0,0.0,1.4146999716758728,1.4310750037431716,2.219129851460457,-3.1596782217044246,-1.1442469489347322,-35.51188530939952,41.96138454048616,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-11,1.3250000476837158,1.4049999713897705,1.3250000476837158,1.399999976158142,65478,0.0,0.0,1.4146999716758728,1.428325003385544,2.197646218538284,-1.039089263592541,-0.9539167680587988,-35.0065997276139,46.44414164151548,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-12,1.315000057220459,1.3799999952316284,1.284999966621399,1.3250000476837158,384688,0.0,0.0,1.4073999762535094,1.4253000050783158,2.1758086681365967,-5.854762680126068,-1.2558779738320984,-34.493320761564505,38.44882103808561,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-13,1.2899999618530273,1.3550000190734863,1.2899999618530273,1.3350000381469727,94167,0.0,0.0,1.3980999827384948,1.4221250057220458,2.1540931860605874,-4.513264099175985,-1.689374906346785,-33.980339619251446,39.933593863806166,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-14,1.3949999809265137,1.3949999809265137,1.274999976158142,1.3250000476837158,92706,0.0,0.0,1.3875999927520752,1.4201500058174132,2.1306291043758394,-4.51138263154663,-2.292012317853901,-33.34597735003524,38.92246012840928,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-17,1.315000057220459,1.3849999904632568,1.2549999952316284,1.315000057220459,60348,0.0,0.0,1.376300001144409,1.417625007033348,2.1095602214336395,-4.453966713142375,-2.9150872539571973,-32.799974486154184,37.88929112750894,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-18,1.3300000429153442,1.3300000429153442,1.2200000286102295,1.2699999809265137,165740,0.0,0.0,1.3585000038146973,1.4128750056028365,2.087729062636693,-6.51453976000542,-3.848535898257955,-32.324791042643774,33.57080800488404,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-19,1.2649999856948853,1.284999966621399,1.190000057220459,1.2450000047683716,150439,0.0,0.0,1.343500006198883,1.4070000052452087,2.066309204697609,-7.331596648755818,-4.513148458393858,-31.907576947027437,31.427726264120423,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-20,1.225000023841858,1.2999999523162842,1.225000023841858,1.284999966621399,136263,0.0,0.0,1.3290000081062316,1.4032250046730042,2.0446805040041607,-3.310763071215545,-5.2896004788675555,-31.371918403631987,38.22302066488728,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-21,1.2649999856948853,1.3250000476837158,1.225000023841858,1.315000057220459,132591,0.0,0.0,1.318500018119812,1.3991000056266785,2.023495437701543,-0.26545019728889185,-5.760845342200137,-30.85726908206453,42.80121479863178,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-24,1.315000057220459,1.3550000190734863,1.25,1.2699999809265137,21070,0.0,0.0,1.3085000157356261,1.3936500042676925,2.000618654489517,-2.9423029687522098,-6.109854574054931,-30.33904781702139,38.22515060823642,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-25,1.2999999523162842,1.2999999523162842,1.2699999809265137,1.274999976158142,16992,0.0,0.0,1.2960000157356262,1.3876250028610229,1.9782869885365169,-1.6203734045145204,-6.603007796521619,-29.857244631247852,39.00546206158224,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-26,1.284999966621399,1.3849999904632568,1.284999966621399,1.309999942779541,108140,0.0,0.0,1.2945000052452087,1.3840250015258788,1.9554724444945653,1.197368672964684,-6.468452244863307,-29.22298621888224,44.308535575558466,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-27,1.309999942779541,1.375,1.2599999904632568,1.3049999475479126,88775,0.0,0.0,1.2914999961853026,1.3810499995946883,1.934165318806966,1.045292404373573,-6.484197055549537,-28.597106660637,43.723691404618215,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-04-28,1.2450000047683716,1.2799999713897705,1.190000057220459,1.225000023841858,100953,0.0,0.0,1.281499993801117,1.376725000143051,1.911494434873263,-4.408893502345778,-6.916777594075772,-27.976510157387324,35.6219994270118,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-02,1.225000023841858,1.375,1.2200000286102295,1.2699999809265137,240938,0.0,0.0,1.2769999861717225,1.372775000333786,1.890089276432991,-0.5481601660931823,-6.976745215987767,-27.369832872418044,42.11885524918747,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-03,1.2699999809265137,1.2699999809265137,1.1799999475479126,1.2050000429153442,92669,0.0,0.0,1.2704999923706055,1.3668999999761582,1.8665933688481648,-5.155446662620278,-7.052455015526673,-26.77033880069749,36.40405525354302,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-04,1.159999966621399,1.190000057220459,1.1200000047683716,1.1399999856948853,187048,0.0,0.0,1.2599999904632568,1.359349998831749,1.8424008856217067,-9.523809974335942,-7.308640780805196,-26.218554851972687,31.762862633366197,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-05,1.190000057220459,1.190000057220459,1.0399999618530273,1.059999942779541,268336,0.0,0.0,1.2374999880790711,1.3496999979019164,1.8190908183654149,-14.34343814217383,-8.312959175910063,-25.80359461575867,27.17138232632543,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-08,1.0399999618530273,1.0399999618530273,0.9900000095367432,1.0049999952316284,244029,0.0,0.0,1.206499981880188,1.3388249963521957,1.7944316923618318,-16.701200967657343,-9.883667755871341,-25.390027268743033,24.544481427482538,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-09,1.0800000429153442,1.0800000429153442,0.9319999814033508,0.9480000138282776,366434,0.0,0.0,1.1742999851703644,1.3270249977707862,1.7708853766322137,-19.271052899592416,-11.508827102502076,-25.06432006940733,22.154020591903844,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-10,0.949999988079071,1.0800000429153442,0.9139999747276306,0.9340000152587891,53546,0.0,0.0,1.140199989080429,1.3150249972939492,1.747609667479992,-18.084544448026193,-13.294424712326686,-24.75293414975317,21.59763992715949,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-11,0.9480000138282776,1.1799999475479126,0.9380000233650208,1.0,200579,0.0,0.0,1.1091999948024749,1.3042249962687493,1.7239157840609551,-9.844932862799112,-14.953324926620827,-24.345202455514276,30.463716475718385,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-12,1.0549999475479126,1.1749999523162842,0.8820000290870667,1.1749999523162842,224466,0.0,0.0,1.0961999952793122,1.2975999936461449,1.7022224093476932,7.188465369122146,-15.520961725725343,-23.77024374015868,47.43686403618028,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-15,1.1649999618530273,1.1649999618530273,1.0149999856948853,1.059999942779541,256544,0.0,0.0,1.0796999871730804,1.2880999907851218,1.67988051623106,-1.8245850354336755,-16.178868496460254,-23.32192805741492,40.44956409214291,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-16,1.100000023841858,1.100000023841858,1.034999966621399,1.0700000524520874,149689,0.0,0.0,1.0596999943256378,1.2795999929308892,1.657583234210809,0.9719786903466284,-17.185057816511584,-22.80327367451211,41.25981641590485,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-17,1.065000057220459,1.1699999570846558,1.034999966621399,1.0499999523162842,123282,0.0,0.0,1.0441999852657318,1.2713999912142753,1.6353516414761544,0.5554460000376668,-17.870065087191932,-22.255253306460578,40.08510692592727,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-19,1.0499999523162842,1.1050000190734863,0.9980000257492065,1.1050000190734863,25703,0.0,0.0,1.040699988603592,1.265324990451336,1.61365584085385,6.178536674740623,-17.75235639403765,-21.586440031611584,44.74415449480627,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-22,1.0800000429153442,1.0800000429153442,1.0,1.0449999570846558,70546,0.0,0.0,1.0391999900341033,1.2555499896407127,1.5903756822148958,0.558118466721894,-17.231492285585535,-21.053245237494803,40.99869144160055,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-23,1.0,1.0399999618530273,1.0,1.0,139730,0.0,0.0,1.0386999905109406,1.2457999899983405,1.568424507478873,-3.7258102305270997,-16.623856249001555,-20.569974260293066,38.40229237026794,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-24,1.0049999952316284,1.1200000047683716,0.9800000190734863,1.034999966621399,46824,0.0,0.0,1.0473999857902527,1.236224989593029,1.5466875488559404,-1.183885749196198,-15.27432347609624,-20.072739286778084,41.5051326727869,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-25,1.0099999904632568,1.1200000047683716,0.9900000095367432,1.1200000047683716,291281,0.0,0.0,1.065999984741211,1.2292249903082848,1.5276727244257926,5.065667992506588,-13.278692416279112,-19.53610412398281,48.31440311870258,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-26,1.1150000095367432,1.1150000095367432,0.9120000004768372,1.0,330583,0.0,0.0,1.065999984741211,1.219274990260601,1.5108722413579623,-6.191368263221272,-12.570995611632283,-19.299927757973467,41.04939064995234,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-29,1.0449999570846558,1.0449999570846558,0.9300000071525574,0.9779999852180481,211069,0.0,0.0,1.0462999880313872,1.2080249905586242,1.4938109745581944,-6.527764847044064,-13.387554379355254,-19.131335146610066,39.865839446184125,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-30,1.034999966621399,1.0499999523162842,0.9800000190734863,1.0049999952316284,264252,0.0,0.0,1.0407999932765961,1.1973999917507172,1.4789497832457223,-3.439661632996737,-13.078336358191919,-19.03714343005699,42.07325989554724,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-05-31,1.0049999952316284,1.100000023841858,0.9900000095367432,0.9919999837875366,164835,0.0,0.0,1.032999986410141,1.1864999920129775,1.4641351670026779,-3.969022571344517,-12.937210841646401,-18.962400551997163,41.28739873902445,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-01,0.9919999837875366,1.0700000524520874,0.9739999771118164,1.065000057220459,101445,0.0,0.0,1.0344999969005584,1.1769249945878983,1.451013242204984,2.9482900349232604,-12.101450673771291,-18.889438059199,47.24618462952186,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-02,1.034999966621399,1.2999999523162842,1.0,1.2350000143051147,880329,0.0,0.0,1.0474999964237213,1.1729249954223633,1.437294175227483,17.89976310468152,-10.69335204622161,-18.393533095845015,57.94929370570908,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-05,1.2350000143051147,1.2350000143051147,1.100000023841858,1.159999966621399,332999,0.0,0.0,1.0589999973773956,1.1661749958992005,1.4224466592073441,9.537296458369113,-9.19030153267569,-18.016258230094238,52.8544052774708,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-07,1.1549999713897705,1.2400000095367432,1.065000057220459,1.2000000476837158,361199,0.0,0.0,1.0790000021457673,1.1606749981641769,1.4092104683319728,11.214091315785007,-7.036853223132551,-17.636504677826988,55.12070115814359,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-08,1.1699999570846558,1.2999999523162842,1.1699999570846558,1.2050000429153442,537861,0.0,0.0,1.0960000097751617,1.1565499991178512,1.3952414015928905,9.945258409490648,-5.235397465641219,-17.107534380970563,55.40924626000294,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-09,1.2050000429153442,1.2949999570846558,1.1200000047683716,1.1699999570846558,155315,0.0,0.0,1.10100000500679,1.150799998641014,1.3822973837455115,6.2670255916520325,-4.327423852366443,-16.747292429739375,52.847836508531,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-12,1.1699999570846558,1.1699999570846558,1.0750000476837158,1.0950000286102295,88782,0.0,0.0,1.110500007867813,1.1450499981641769,1.3681474675734837,-1.3957657944860309,-3.0173346449287517,-16.306536736495783,47.75359732132877,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-13,1.0700000524520874,1.2949999570846558,1.0,1.2949999570846558,255729,0.0,0.0,1.1422000050544738,1.144049996137619,1.3645172089338302,13.377687914026456,-0.16170544026841288,-16.157158836309147,59.08100952152277,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-14,1.284999966621399,1.284999966621399,1.0199999809265137,1.1050000190734863,179319,0.0,0.0,1.1522000074386596,1.1385499954223632,1.3599542260169983,-4.096509986152388,1.198894389458291,-16.280270788457237,48.35528656706069,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-15,1.1050000190734863,1.1200000047683716,1.0199999809265137,1.0499999523162842,64872,0.0,0.0,1.1580000042915344,1.131924992799759,1.3558468669652939,-9.32642932426626,2.303598883109751,-16.515277618830584,45.765232775603025,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-16,1.0299999713897705,1.0850000381469727,0.921999990940094,0.9959999918937683,363205,0.0,0.0,1.1510999977588654,1.1250749930739403,1.3519091422359149,-13.4740688182668,2.313179552042066,-16.778801331782905,43.31227150359997,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-19,1.0499999523162842,1.0499999523162842,0.9259999990463257,0.9879999756813049,158821,0.0,0.0,1.1263999938964844,1.1186499923467637,1.3472386419773101,-12.286933501874499,0.692799499641738,-16.967198127204274,42.945031443432725,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-20,0.9800000190734863,1.0449999570846558,0.972000002861023,1.0399999618530273,106154,0.0,0.0,1.1143999934196471,1.1125249922275544,1.3412045419216156,-6.676241206563175,0.16853564685666025,-17.050311309445746,46.14163861550887,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-21,1.0299999713897705,1.0299999713897705,0.9760000109672546,0.984000027179718,144242,0.0,0.0,1.0927999913692474,1.1042499914765358,1.3343010172247887,-9.956072936384832,-1.0369028929742727,-17.241313824877068,43.32638679905076,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-22,1.024999976158142,1.0299999713897705,0.9679999947547913,0.9980000257492065,72028,0.0,0.0,1.0720999896526338,1.097449992597103,1.3284591004252433,-6.911665387426784,-2.3099005071273293,-17.389252537333938,44.24229983518276,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-26,0.984000027179718,1.024999976158142,0.9660000205039978,1.024999976158142,27065,0.0,0.0,1.0575999915599823,1.0911999925971032,1.323833592236042,-3.082452312972743,-3.0791790015642735,-17.572722206422135,46.053055485128986,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-27,1.024999976158142,1.024999976158142,0.47999998927116394,0.6000000238418579,2444465,0.0,0.0,1.0080999910831452,1.073449994623661,1.3156974002718926,-40.48209213877757,-6.087847954522264,-18.412091229956857,29.701866531678377,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-28,0.6060000061988831,0.6880000233650208,0.5,0.5559999942779541,562019,0.0,0.0,0.934199994802475,1.054724995791912,1.3055370256304741,-40.4838367189765,-11.427149396316725,-19.21140687047456,28.570865365825256,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-29,0.5400000214576721,0.5540000200271606,0.5,0.527999997138977,403450,0.0,0.0,0.876499992609024,1.03729999512434,1.2961657091975212,-39.760410542924056,-15.501783791683243,-19.97165271664604,27.84425006658998,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-06-30,0.5379999876022339,0.5379999876022339,0.46399998664855957,0.48399999737739563,249571,0.0,0.0,0.8198999971151352,1.0176499955356122,1.287171284109354,-40.96841089396546,-19.432024692968895,-20.939038331657205,26.695314799945493,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-03,0.47999998927116394,0.47999998927116394,0.4000000059604645,0.42899999022483826,488254,0.0,0.0,0.7631999969482421,0.9982499942183495,1.277935401101907,-43.78930923214722,-23.5462057231622,-21.88572338182331,25.290521047668477,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-04,0.42100000381469727,0.4399999976158142,0.3799999952316284,0.41999998688697815,472850,0.0,0.0,0.7063999980688095,0.9802499942481517,1.2695074923336507,-40.54360305277542,-27.936750603032056,-22.785017011106902,25.05814516669011,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-05,0.4359999895095825,0.44699999690055847,0.41100001335144043,0.41999998688697815,76736,0.0,0.0,0.6444000005722046,0.9642499953508377,1.2610176175832748,-34.82309334046665,-33.1708577983718,-23.53397907328121,25.05814516669011,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-06,0.4020000100135803,0.42100000381469727,0.38100001215934753,0.4169999957084656,329925,0.0,0.0,0.5876999974250794,0.9495499953627586,1.2516352588931718,-29.045431761870105,-38.1075245858372,-24.13524718036059,24.969452244993917,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-07,0.25,0.30000001192092896,0.17299999296665192,0.26600000262260437,6202961,0.0,0.0,0.5144999951124192,0.9324999950826168,1.2414592924217382,-48.29931872701322,-44.82573749860064,-24.88678438552976,20.95000910175908,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-10,0.2680000066757202,0.2939999997615814,0.23999999463558197,0.23999999463558197,793759,0.0,0.0,0.4359999969601631,0.9151499945670366,1.2310666592170796,-44.95412928695261,-52.35753706511931,-25.66202750149665,20.34278565197924,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-11,0.23999999463558197,0.27900001406669617,0.23999999463558197,0.23999999463558197,369843,0.0,0.0,0.3999999940395355,0.8961499944329262,1.2204416672388712,-40.000000447034836,-55.364615686612694,-26.571665120187422,20.34278565197924,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-12,0.2549999952316284,0.27399998903274536,0.22300000488758087,0.27000001072883606,431614,0.0,0.0,0.37139999568462373,0.87352499589324,1.2102083337803682,-27.302096428103358,-57.48261384268214,-27.820279243609175,23.317056186908857,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-13,0.27900001406669617,0.3700000047683716,0.27000001072883606,0.33000001311302185,656044,0.0,0.0,0.3515999972820282,0.855274997651577,1.1999583343664806,-6.143340254829517,-58.890415568389685,-28.724608750426285,29.02494561132397,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-14,0.33000001311302185,0.36899998784065247,0.2849999964237213,0.3149999976158142,1465961,0.0,0.0,0.3346999973058701,0.8363999962806702,1.1899500007430712,-5.885867896214162,-59.9832617414844,-29.711332765378767,28.454707778209468,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-17,0.3199999928474426,0.3400000035762787,0.2720000147819519,0.3140000104904175,273399,0.0,0.0,0.323199999332428,0.8179999977350235,1.1804666673143704,-2.8465312069966444,-60.48899752721969,-30.705370987219776,28.414629044823457,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-18,0.2809999883174896,0.29899999499320984,0.2759999930858612,0.27799999713897705,317622,0.0,0.0,0.30900000035762787,0.7973249971866607,1.1702833339571952,-10.03236348957032,-61.24541417264906,-31.869063324127968,26.94332000288533,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-19,0.27799999713897705,0.3199999928474426,0.2759999930858612,0.28999999165534973,304728,0.0,0.0,0.29600000083446504,0.7784499980509281,1.1606166668236255,-2.0270301223650167,-61.97572078160633,-32.927897702745454,28.276492971351033,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-20,0.3089999854564667,0.3089999854564667,0.26600000262260437,0.29499998688697815,216386,0.0,0.0,0.2837999999523163,0.7608249977231025,1.1509083330631256,3.946436552693323,-62.69838651442371,-33.8935190695702,28.859024730464014,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-21,0.27399998903274536,0.2939999997615814,0.2540000081062317,0.2800000011920929,268237,0.0,0.0,0.28519999980926514,0.7419499985873699,1.141041666517655,-1.8232814237902784,-61.56075202476319,-34.976081911914136,28.121126046272153,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-24,0.2800000011920929,0.36000001430511475,0.25,0.3529999852180481,1864502,0.0,0.0,0.29649999886751177,0.7227749980986118,1.1318166660765807,19.055644710401097,-58.9775518456632,-36.14027609223175,36.615213377175714,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-25,0.3529999852180481,0.36000001430511475,0.30000001192092896,0.32899999618530273,250071,0.0,0.0,0.3053999990224838,0.7059999980032444,1.1223583328227202,7.727569495205354,-56.742209647841904,-37.09673841618289,35.14476734061866,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-26,0.32899999618530273,0.32899999618530273,0.2709999978542328,0.31299999356269836,162460,0.0,0.0,0.30969999730587006,0.6893749982118607,1.1124999990065894,1.0655461044673893,-55.075249594315544,-38.03370797056716,34.15985576002362,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-27,0.3100000023841858,0.3190000057220459,0.28700000047683716,0.3179999887943268,187203,0.0,0.0,0.30849999487400054,0.6721999980509281,1.1028499993185201,3.079414612050898,-54.10592148638662,-39.04882817551815,34.77501110913644,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-28,0.32899999618530273,0.33899998664855957,0.30000001192092896,0.3310000002384186,752384,0.0,0.0,0.31009999513626096,0.6556749984622001,1.093358332415422,6.739763118336699,-52.70522806824114,-40.031096940222874,36.437854718176496,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-07-31,0.3310000002384186,0.3479999899864197,0.3310000002384186,0.3479999899864197,60573,0.0,0.0,0.3134999930858612,0.6377499967813491,1.0837249994277953,11.004783943044508,-50.84280757850889,-41.15204529580107,38.640814585672544,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-01,0.3569999933242798,0.3569999933242798,0.3019999861717224,0.3199999928474426,445742,0.0,0.0,0.3176999926567078,0.6148749962449074,1.0744583323597907,0.7239534919410958,-48.33096245628331,-42.773490816113686,36.402926575996986,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-02,0.3149999976158142,0.31700000166893005,0.3019999861717224,0.3109999895095825,49596,0.0,0.0,0.31979999244213103,0.593649996817112,1.0646499986449878,-2.751720806916812,-46.12987548947077,-44.239891271998474,35.68747981304304,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-03,0.3140000104904175,0.3149999976158142,0.28999999165534973,0.3149999976158142,214054,0.0,0.0,0.32179999351501465,0.5715249955654145,1.0549749990304311,-2.113112503491447,-43.694502250657436,-45.82573083810789,36.286819713493564,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-04,0.3140000104904175,0.3440000116825104,0.30000001192092896,0.33000001311302185,459620,0.0,0.0,0.3267999947071075,0.5496499948203564,1.0457583325604598,0.9791978144866024,-40.543982937011315,-47.44005591860023,38.597701918211925,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-07,0.3050000071525574,0.3089999854564667,0.3050000071525574,0.3089999854564667,71305,0.0,0.0,0.3223999947309494,0.5281249955296516,1.0357499991854031,-4.156330488052687,-38.953846634807086,-49.01037934395255,36.59645627058853,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-08,0.3100000023841858,0.3400000035762787,0.3100000023841858,0.335999995470047,1226063,0.0,0.0,0.32309999465942385,0.5091499947011471,1.0264999993145465,3.992572276028941,-36.54129470254202,-50.399415972612175,40.843348841212915,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-09,0.3400000035762787,0.3400000035762787,0.28600001335144043,0.33399999141693115,329433,0.0,0.0,0.3251999944448471,0.485124995559454,1.0170999991397063,2.706026175402198,-32.96573101333993,-52.30311710060099,40.62627058020155,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-10,0.33399999141693115,0.33399999141693115,0.28999999165534973,0.3050000071525574,352239,0.0,0.0,0.3238999962806702,0.46512499526143075,1.0079416655004025,-5.835131011157942,-30.362805787588957,-53.85397675464534,37.51292394840214,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-11,0.29499998688697815,0.3160000145435333,0.29499998688697815,0.30000001192092896,17704,0.0,0.0,0.3207999974489212,0.44637499675154685,0.998641665528218,-6.483786064027032,-28.132175909602065,-55.30178519885379,36.98663786473633,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-14,0.30000001192092896,0.3109999895095825,0.28700000047683716,0.30000001192092896,78560,0.0,0.0,0.31599999964237213,0.4289749972522259,0.9889749986430009,-5.063287259351552,-26.33603317990756,-56.624282935278046,36.98663786473633,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-15,0.31200000643730164,0.31200000643730164,0.28999999165534973,0.28999999165534973,5512,0.0,0.0,0.3129999995231628,0.411524997651577,0.9790583317478497,-7.3482453363745215,-23.941437018567623,-57.96726463510014,35.82095922659846,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-16,0.28999999165534973,0.3050000071525574,0.27399998903274536,0.28299999237060547,102439,0.0,0.0,0.31019999980926516,0.3925999984145164,0.9694499984383583,-8.768538831523001,-20.98828296943888,-59.50281097045361,34.989663501087875,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-17,0.30000001192092896,0.3070000112056732,0.2800000011920929,0.29600000381469727,45232,0.0,0.0,0.30830000042915345,0.3753999978303909,0.959583331644535,-3.989619395826986,-17.874266859094078,-60.87885382637588,37.873214531350946,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-18,0.29600000381469727,0.29600000381469727,0.2800000011920929,0.2939999997615814,34688,0.0,0.0,0.3046999990940094,0.3577999971807003,0.9496333313484987,-3.5116505954194994,-14.840692706845868,-62.322300053156624,37.59692187489302,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-21,0.2800000011920929,0.30799999833106995,0.2800000011920929,0.2849999964237213,70239,0.0,0.0,0.3023000001907349,0.33929999768733976,0.9393749977151553,-5.722793171054651,-10.90480334476744,-63.88023967929526,36.313122251500985,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-22,0.2849999964237213,0.3070000112056732,0.2849999964237213,0.2849999964237213,51342,0.0,0.0,0.2972000002861023,0.3314249970018864,0.9296333310504754,-4.104981107212825,-10.326619001399374,-64.34884745070622,36.313122251500985,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-23,0.3070000112056732,0.3070000112056732,0.27399998903274536,0.27799999713897705,22601,0.0,0.0,0.2916000008583069,0.32447499707341193,0.9200833308200042,-4.663924444204067,-10.131750215461786,-64.73417285103615,35.22805098765056,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-24,0.2849999964237213,0.2849999964237213,0.2680000066757202,0.27000001072883606,55528,0.0,0.0,0.28810000121593476,0.31802499741315843,0.9106833308935165,-6.282537455989985,-9.409636487897508,-65.07842115643774,33.97844219797824,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-25,0.2840000092983246,0.30799999833106995,0.2639999985694885,0.27300000190734863,247195,0.0,0.0,0.28540000021457673,0.31274999752640725,0.9010583311319351,-4.344778660793699,-8.745003206441657,-65.29081561972556,34.91085755248035,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-28,0.29499998688697815,0.29499998688697815,0.2639999985694885,0.2639999985694885,82765,0.0,0.0,0.2817999988794327,0.3086249977350235,0.891258330643177,-6.316536685849967,-8.691777740771983,-65.37199293135313,33.387456133405735,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-29,0.2630000114440918,0.2630000114440918,0.21799999475479126,0.23399999737739563,430651,0.0,0.0,0.27619999945163726,0.30397499799728395,0.8811916636923949,-15.278784271551334,-9.137264159434212,-65.50409967298611,28.86577128322537,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-30,0.23399999737739563,0.25200000405311584,0.20000000298023224,0.21899999678134918,508565,0.0,0.0,0.26979999989271164,0.2989499982446432,0.8709666638324658,-18.828763206658092,-9.750793953200459,-65.6760688257355,26.90383104625741,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-08-31,0.21899999678134918,0.22100000083446503,0.1850000023841858,0.19200000166893005,465881,0.0,0.0,0.25939999967813493,0.29332499839365483,0.8605666633695364,-25.98303704426954,-11.565669104680634,-65.91490109027173,23.771827337147272,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-01,0.20000000298023224,0.20900000631809235,0.1899999976158142,0.20900000631809235,329534,0.0,0.0,0.250900000333786,0.29189999848604203,0.8504749971131483,-16.699878023097572,-14.045905572081235,-65.67800353016054,29.34879054624318,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-04,0.2199999988079071,0.24899999797344208,0.20999999344348907,0.22100000083446503,161340,0.0,0.0,0.2445000007748604,0.2914249986410141,0.8405333301673333,-9.611451887901854,-16.101912356515893,-65.32856126205046,33.07110140664807,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-05,0.20600000023841858,0.23899999260902405,0.20600000023841858,0.23899999260902405,165524,0.0,0.0,0.23990000039339066,0.29139999859035015,0.8305916630973419,-0.3751595593542163,-17.67330077079312,-64.9165755524566,38.32050306348499,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-06,0.23999999463558197,0.27000001072883606,0.2240000069141388,0.25,288400,0.0,0.0,0.23710000067949294,0.29089999832212926,0.8206749959538381,5.440742000648504,-18.494327244051988,-64.55356873837398,41.34800393139471,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-07,0.24899999797344208,0.24899999797344208,0.22699999809265137,0.22699999809265137,44198,0.0,0.0,0.23279999941587448,0.28832499794662,0.810566662127773,-2.4914095093539834,-19.257781644387734,-64.42920595947602,37.23282246166814,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-08,0.20399999618530273,0.2980000078678131,0.20399999618530273,0.2809999883174896,133065,0.0,0.0,0.23359999805688858,0.28747499771416185,0.8011583289752404,20.29109188993132,-18.740760095888934,-64.11757984443969,49.85217415278232,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-11,0.3499999940395355,0.3499999940395355,0.29600000381469727,0.31200000643730164,465899,0.0,0.0,0.23839999884366989,0.28742499761283397,0.7922749955207109,30.872486556467955,-17.056623180424108,-63.72156142275723,55.39624549851839,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-12,0.31200000643730164,0.3230000138282776,0.29600000381469727,0.3109999895095825,27206,0.0,0.0,0.2460999980568886,0.2882499974220991,0.7836333283533653,26.37139047749672,-14.622723240995604,-63.21621516177807,55.184300909264444,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-13,0.3160000145435333,0.3160000145435333,0.3009999990463257,0.3160000145435333,8115,0.0,0.0,0.255799999833107,0.2888999979943037,0.7742999952286482,23.534016712159104,-11.457251087225478,-62.68888030807847,56.08891976186517,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-14,0.3160000145435333,0.3190000057220459,0.29499998688697815,0.29499998688697815,121684,0.0,0.0,0.2660999983549118,0.2888999979943037,0.7651749952385823,10.860574487310165,-7.892004083655771,-62.24393115404608,51.39645524357527,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-15,0.30000001192092896,0.3070000112056732,0.29499998688697815,0.29499998688697815,7465,0.0,0.0,0.2746999964118004,0.28927499763667586,0.755816661939025,7.389876498122059,-5.038458679094493,-61.72682977184579,51.39645524357527,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-18,0.2849999964237213,0.29499998688697815,0.25999999046325684,0.29499998688697815,37579,0.0,0.0,0.2820999950170517,0.2878249976783991,0.7466083286950985,4.5728437071212,-1.9890567905933676,-61.44899720293079,51.39645524357527,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-19,0.29499998688697815,0.296999990940094,0.2639999985694885,0.296999990940094,27612,0.0,0.0,0.2878999948501587,0.28702499754726885,0.7374333286037048,3.1608184274791293,0.3048505566996021,-61.07783762760802,51.875367996929796,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-20,0.296999990940094,0.296999990940094,0.25,0.25999999046325684,90947,0.0,0.0,0.28889999389648435,0.2856999974697828,0.7276999954134226,-10.00346280505034,1.1200547620025776,-60.73931575230116,43.362788224720944,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-21,0.25099998712539673,0.26899999380111694,0.25,0.25,61728,0.0,0.0,0.29119999408721925,0.2839999977499247,0.71786666251719,-14.148349905144286,2.535209998006585,-60.43833589456816,41.38610490278653,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-22,0.27300000190734863,0.27300000190734863,0.2199999988079071,0.24899999797344208,526842,0.0,0.0,0.2879999950528145,0.28194999769330026,0.708041662722826,-13.541665885174908,2.145769607735658,-60.1788972969414,41.183927025815926,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-25,0.23199999332427979,0.23999999463558197,0.22499999403953552,0.23999999463558197,140373,0.0,0.0,0.28079999387264254,0.2792499978095293,0.6979749963929256,-14.529914575270789,0.5550567861312771,-59.99140381064234,39.32208802937055,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-26,0.23000000417232513,0.23999999463558197,0.23000000417232513,0.23999999463558197,27399,0.0,0.0,0.27369999438524245,0.27724999785423277,0.6883499965071678,-12.31275134855375,-1.2804340834861858,-59.72252498568208,39.32208802937055,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-27,0.23999999463558197,0.2669999897480011,0.22599999606609344,0.23999999463558197,114982,0.0,0.0,0.2660999923944473,0.2754749979823828,0.6784333302328984,-9.808342166420134,-3.4032146861237194,-59.39542093431416,39.32208802937054,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-28,0.25999999046325684,0.26499998569488525,0.23899999260902405,0.2529999911785126,29804,0.0,0.0,0.26189999282360077,0.27392499782145024,0.6687083305170138,-3.3982443256814725,-4.389889602440597,-59.03670025919009,43.89770449867724,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-09-29,0.2639999985694885,0.2680000066757202,0.23800000548362732,0.2680000066757202,54966,0.0,0.0,0.25919999480247496,0.2723749976605177,0.6595249971995751,3.3950663772008776,-4.8370823207729865,-58.70133826359035,48.704254729467465,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-02,0.24500000476837158,0.2800000011920929,0.24300000071525574,0.2800000011920929,116005,0.0,0.0,0.25769999623298645,0.2716499980539083,0.6501916640748581,8.65347508152271,-5.1352850803825625,-58.22001218049565,52.2302357864883,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-03,0.2800000011920929,0.2800000011920929,0.24400000274181366,0.25600001215934753,199543,0.0,0.0,0.2535999983549118,0.26964999847114085,0.6412833304454882,0.9463776892762091,-5.952160284527789,-57.95150354464699,45.494673421812564,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-04,0.2409999966621399,0.26100000739097595,0.2409999966621399,0.2529999911785126,69432,0.0,0.0,0.2528999984264374,0.2676249984651804,0.6322666633874178,0.03953845500092347,-5.502101867609653,-57.6721320350248,44.71836249429474,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-05,0.23999999463558197,0.2549999952316284,0.20000000298023224,0.2199999988079071,1195188,0.0,0.0,0.2498999983072281,0.2654999982565641,0.6230583296467861,-11.964785795061031,-5.875706234190282,-57.38761755948645,37.19900544818563,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-06,0.210999995470047,0.21899999678134918,0.20000000298023224,0.21899999678134918,134969,0.0,0.0,0.2468999981880188,0.26347499787807466,0.6139249958097934,-11.300122159346177,-6.290919375099902,-57.0835200266541,36.99599366983237,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-09,0.20200000703334808,0.21199999749660492,0.20000000298023224,0.20000000298023224,21933,0.0,0.0,0.24289999902248383,0.26097499765455723,0.6050083293269078,-17.661587573032715,-6.925950299652304,-56.86423062226255,33.279726583850376,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-10,0.20800000429153442,0.20800000429153442,0.20000000298023224,0.20000000298023224,107849,0.0,0.0,0.23889999985694885,0.2587249979376793,0.5962999959786733,-16.2829622854791,-7.662575413569354,-56.61160495011431,33.279726583850376,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-11,0.19949999451637268,0.20000000298023224,0.1899999976158142,0.19949999451637268,254468,0.0,0.0,0.2348499998450279,0.25663749799132346,0.5872541628777981,-15.05216323269401,-8.489600435175749,-56.2987349917301,33.17800905350455,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-12,0.19499999284744263,0.20100000500679016,0.1899999976158142,0.20100000500679016,77044,0.0,0.0,0.22965000122785567,0.25426249802112577,0.5779708291093508,-12.475504492873643,-9.679955551771986,-56.00772820785046,33.8313948077997,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-13,0.20999999344348907,0.20999999344348907,0.1899999976158142,0.2029999941587448,113099,0.0,0.0,0.22314999997615814,0.2519874978810549,0.5690791625529528,-9.029803190484518,-11.444019305477154,-55.72013272272862,34.74754178803329,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-16,0.20000000298023224,0.2070000022649765,0.18950000405311584,0.20000000298023224,5757,0.0,0.0,0.21515000015497207,0.24986249804496766,0.5601208294431369,-7.041597566268799,-13.892640216759697,-55.39132185221948,33.98737683600275,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-17,0.20000000298023224,0.20600000023841858,0.19300000369548798,0.20600000023841858,2173,0.0,0.0,0.21014999896287917,0.2478874981403351,0.5509208299219608,-1.9747793218850527,-15.223639538324685,-55.00487825529326,36.957881985827676,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-18,0.20000000298023224,0.2029999941587448,0.20000000298023224,0.20200000703334808,31467,0.0,0.0,0.20505000054836273,0.24598749838769435,0.5417291637510061,-1.487438920681825,-16.642105028773095,-54.592162496025956,35.801252074435865,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-19,0.20000000298023224,0.20000000298023224,0.19699999690055847,0.19699999690055847,28000,0.0,0.0,0.20275000035762786,0.24416249804198742,0.5331624968598286,-2.8360066322698083,-16.96103947840428,-54.204862592542945,34.35394631011037,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-20,0.19949999451637268,0.20900000631809235,0.19099999964237213,0.19200000166893005,107103,0.0,0.0,0.20005000084638597,0.24213749803602697,0.5241791636993488,-4.023993573305372,-17.381651966759364,-53.80634813349644,32.92071994184579,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-23,0.18700000643730164,0.2460000067949295,0.18700000643730164,0.2280000001192093,60583,0.0,0.0,0.20285000056028366,0.24123749807476996,0.5160374966760476,12.398323632960242,-15.912740689504398,-53.25194397138714,49.316221780317115,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-24,0.2280000001192093,0.2280000001192093,0.1899999976158142,0.19499999284744263,186313,0.0,0.0,0.2023499995470047,0.24026249796152116,0.5081624967356523,-3.632323556222546,-15.779615518934746,-52.71935660247937,39.72993507539375,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-25,0.18649999797344208,0.19949999451637268,0.17000000178813934,0.18150000274181366,806959,0.0,0.0,0.2005500003695488,0.23932499811053276,0.5008416639020046,-9.498876884882645,-16.201816796035516,-52.21543746061841,36.59594457424979,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-26,0.17499999701976776,0.17649999260902405,0.15000000596046448,0.17550000548362732,201923,0.0,0.0,0.1980000004172325,0.2389124982059002,0.49392916398743786,-11.363633780905259,-17.12446945885952,-51.63021023557612,35.26450961919686,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-27,0.17550000548362732,0.17550000548362732,0.1550000011920929,0.15950000286102295,349487,0.0,0.0,0.19365000128746032,0.23767499811947346,0.4873583305627108,-17.63490740996382,-18.523192250066973,-51.231982052086686,31.928556330867224,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-30,0.1899999976158142,0.1899999976158142,0.16050000488758087,0.1704999953508377,88336,0.0,0.0,0.19070000052452088,0.23641249798238279,0.48099583039681115,-10.592556433205559,-19.33590560904625,-50.84936645139988,36.38413932034609,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-10-31,0.18000000715255737,0.18000000715255737,0.16949999332427979,0.17000000178813934,37326,0.0,0.0,0.18710000067949295,0.23468749821186066,0.47407916374504566,-9.139496969134884,-20.276963150976542,-50.4961373206284,36.267935843519126,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-01,0.164000004529953,0.1899999976158142,0.164000004529953,0.17000000178813934,132644,0.0,0.0,0.18390000015497207,0.23268749825656415,0.46570416415731114,-7.558454787993058,-20.966961468552288,-50.0353408525752,36.267935843519126,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-02,0.16200000047683716,0.16949999332427979,0.16050000488758087,0.16050000488758087,19175,0.0,0.0,0.18025000095367433,0.23102499842643737,0.45820833134154476,-10.957001920443462,-21.97813994961707,-49.580794886456744,33.8833047846618,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-03,0.1599999964237213,0.16500000655651093,0.1599999964237213,0.164000004529953,32371,0.0,0.0,0.1774500012397766,0.22809999883174897,0.45065833094219365,-7.579597980193591,-22.205172227700356,-49.385158739912974,35.56425341615649,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-06,0.16300000250339508,0.20000000298023224,0.15649999678134918,0.18000000715255737,150426,0.0,0.0,0.17265000194311142,0.22479999884963037,0.44340833139916264,4.257170649710041,-23.198397319122005,-49.301809882489074,42.73213811070297,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-07,0.18000000715255737,0.18000000715255737,0.15549999475479126,0.16099999845027924,269520,0.0,0.0,0.16925000250339509,0.22104999907314776,0.43554166456063587,-4.87444840832446,-23.43361085136739,-49.2471060613368,37.41017011964725,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-08,0.18799999356269836,0.18799999356269836,0.16099999845027924,0.17599999904632568,41950,0.0,0.0,0.16870000213384628,0.2175499986857176,0.4282999982436498,4.327206176729978,-22.454606686733282,-49.206164002373285,43.40301567934193,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-09,0.16249999403953552,0.17800000309944153,0.16249999403953552,0.17249999940395355,31594,0.0,0.0,0.16840000152587892,0.21448749899864197,0.42140416490534943,2.4346780528054603,-21.487265079749406,-49.10171354219589,42.38328534257572,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-10,0.16949999332427979,0.17249999940395355,0.16300000250339508,0.17249999940395355,21189,0.0,0.0,0.16970000118017198,0.21142499931156636,0.4142166651785374,1.6499694780843237,-19.735129841436752,-48.95787227188528,42.38328534257572,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-13,0.17249999940395355,0.17249999940395355,0.1589999943971634,0.15950000286102295,208155,0.0,0.0,0.16860000193119049,0.20803749971091748,0.4062124984959761,-5.397389659509882,-18.956917783826537,-48.78604167001566,38.48803172639154,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-14,0.1599999964237213,0.1655000001192093,0.15600000321865082,0.1655000001192093,107451,0.0,0.0,0.16815000176429748,0.20474999994039536,0.39925833183030285,-1.575974794697179,-17.875456989866905,-48.717413359473625,41.17519535998193,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-15,0.17000000178813934,0.17000000178813934,0.15000000596046448,0.15950000286102295,202167,0.0,0.0,0.16710000187158586,0.2022375002503395,0.39243749864399435,-4.548174102597202,-17.3743733656017,-48.466316050545835,39.32512077167256,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-16,0.1615000069141388,0.17800000309944153,0.1550000011920929,0.1599999964237213,152931,0.0,0.0,0.1670500010251999,0.19998750016093253,0.3853958319872618,-4.220296054003063,-16.469778915795935,-48.108546184915,39.56879682663804,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-17,0.19599999487400055,0.19599999487400055,0.15549999475479126,0.1599999964237213,51267,0.0,0.0,0.1666500002145767,0.19776250012218952,0.37846249875923,-3.9904013095067055,-15.732254541882126,-47.745813450330274,39.56879682663805,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-20,0.1550000011920929,0.19750000536441803,0.1550000011920929,0.15700000524520874,131167,0.0,0.0,0.16435000002384187,0.19568750038743019,0.37089583165943624,-4.47215988899719,-16.014053172300244,-47.2392290007955,38.493047310595834,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-21,0.1599999964237213,0.17000000178813934,0.15700000524520874,0.15700000524520874,2711,0.0,0.0,0.16395000070333482,0.19361250065267085,0.3619124982506037,-4.239094497292498,-15.32054998997651,-46.50295262292785,38.493047310595834,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-22,0.1599999964237213,0.16500000655651093,0.1599999964237213,0.16500000655651093,6543,0.0,0.0,0.16285000145435333,0.19173750095069408,0.3536208319167296,1.3202364648183575,-15.066170860216474,-45.778787999728394,43.263507193074645,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-23,0.17000000178813934,0.17000000178813934,0.15000000596046448,0.15000000596046448,81114,0.0,0.0,0.16060000211000441,0.18916250132024287,0.34487083156903586,-6.600246581740002,-15.099451006879816,-45.14975347157577,37.405412505204566,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-24,0.15000000596046448,0.1860000044107437,0.14800000190734863,0.1599999964237213,377896,0.0,0.0,0.1593500018119812,0.1864625010639429,0.33616249784827235,0.40790373664824525,-14.540456712346748,-44.532033686844166,42.951327400432156,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-27,0.17949999868869781,0.18000000715255737,0.15049999952316284,0.16349999606609344,264129,0.0,0.0,0.15975000113248825,0.18355000093579293,0.3277749981731176,2.347414652282319,-12.96649397001643,-44.00121975171237,44.79493480496865,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-28,0.164000004529953,0.164000004529953,0.12099999934434891,0.12399999797344208,1985158,0.0,0.0,0.15560000091791154,0.1802500005811453,0.3196833312511444,-20.308485063017695,-13.675450531905417,-43.61607786189508,32.16251270460026,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-29,0.11999999731779099,0.1404999941587448,0.1120000034570694,0.14000000059604645,577739,0.0,0.0,0.15365000069141388,0.17742500081658363,0.31005833161373936,-8.88382690136246,-13.400028189796995,-42.77689623976499,39.59353865093928,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-11-30,0.14000000059604645,0.16750000417232513,0.14000000059604645,0.15000000596046448,441035,0.0,0.0,0.15265000164508818,0.17567500099539757,0.3020999981711308,-1.7359945339437053,-13.1065884274067,-41.84872490602174,43.74147629031542,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-01,0.15000000596046448,0.15700000524520874,0.13099999725818634,0.14550000429153442,227481,0.0,0.0,0.1512000024318695,0.1738375011831522,0.2945624986042579,-3.769839979270833,-13.022218219434828,-40.98451024592193,42.33276315121095,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-04,0.14000000059604645,0.14000000059604645,0.13050000369548798,0.13899999856948853,205338,0.0,0.0,0.1494000017642975,0.1723125010728836,0.2874208319932222,-6.961180101735636,-13.29706153989067,-40.048708412009965,40.31317913608041,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-05,0.1315000057220459,0.14350000023841858,0.12800000607967377,0.13449999690055847,247892,0.0,0.0,0.14715000092983246,0.17067500092089177,0.28030833217004936,-8.596672748446712,-13.783506585105101,-39.11169190027801,38.92853864360609,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-06,0.1315000057220459,0.15700000524520874,0.1289999932050705,0.13950000703334808,144902,0.0,0.0,0.14460000097751619,0.16917500123381615,0.2728041658798854,-3.526966742525194,-14.52637805649249,-37.98665035478114,41.33943805867752,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-07,0.13050000369548798,0.13950000703334808,0.1289999932050705,0.13850000500679016,122164,0.0,0.0,0.14345000088214874,0.16761250123381616,0.26575833236177765,-3.450676782794335,-14.415691057531088,-36.93048125932521,40.99090580560591,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-08,0.12999999523162842,0.12999999523162842,0.1289999932050705,0.1289999932050705,86244,0.0,0.0,0.14035000056028366,0.1657625012099743,0.25851666542390983,-8.086930751623376,-15.330669158702047,-35.87937515047216,37.73597384149396,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-11,0.1289999932050705,0.13500000536441803,0.1289999932050705,0.12999999523162842,71392,0.0,0.0,0.13700000047683716,0.1640125010162592,0.25105833224952223,-5.1094928619305,-16.469781493511995,-34.67155638823801,38.291444595936994,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-12,0.12999999523162842,0.13950000703334808,0.12349999696016312,0.12700000405311584,161775,0.0,0.0,0.13730000108480453,0.16203750111162663,0.24711666541794935,-7.501818609110428,-15.266527721740527,-34.428744076174716,37.218717661717406,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-13,0.12549999356269836,0.12600000202655792,0.12300000339746475,0.12399999797344208,295277,0.0,0.0,0.1357000008225441,0.16008750088512896,0.2435166654487451,-8.62196225363492,-15.233856439600585,-34.260145772723774,36.12871687267165,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-14,0.12200000137090683,0.1445000022649765,0.12200000137090683,0.125,323499,0.0,0.0,0.13320000022649764,0.158287500962615,0.2401583321392536,-6.156156315731299,-15.849325173212915,-34.09035632757749,36.793213144246586,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-15,0.12999999523162842,0.13349999487400055,0.10300000011920929,0.12099999934434891,691620,0.0,0.0,0.1307499997317791,0.15651250090450047,0.2371333321556449,-7.4569792791062,-16.46034727183929,-33.998101624206974,35.21502500737947,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-18,0.11999999731779099,0.11999999731779099,0.10649999976158142,0.11649999767541885,311895,0.0,0.0,0.12849999964237213,0.15372500084340573,0.2345291655510664,-9.338522957471158,-16.40917291438458,-34.45378084120048,33.47540576151199,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-19,0.11299999803304672,0.12150000035762787,0.10750000178813934,0.12150000035762787,444570,0.0,0.0,0.12719999998807907,0.15188750103116036,0.23204166566332182,-4.481131785365877,-16.253806847488093,-34.54300519823894,37.18827108287085,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-20,0.12099999934434891,0.12099999934434891,0.11500000208616257,0.11800000071525574,150522,0.0,0.0,0.12504999935626984,0.1503000009804964,0.22952499911189078,-5.637743844307047,-16.799734836663845,-34.51693647225465,35.68679985942477,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-21,0.11800000071525574,0.12150000035762787,0.1145000010728836,0.12049999833106995,337563,0.0,0.0,0.12324999868869782,0.14892500080168247,0.2270541658004125,-2.2312376364187765,-17.24022291406601,-34.409923607130786,37.62404469999558,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-22,0.12150000035762787,0.12150000035762787,0.10999999940395355,0.12150000035762787,166596,0.0,0.0,0.12249999940395355,0.14797500073909758,0.22584999911487103,-0.8163257560745808,-17.215746719312634,-34.48084953773453,38.42304795784576,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-27,0.12150000035762787,0.12150000035762787,0.11100000143051147,0.11500000208616257,265252,0.0,0.0,0.12100000008940696,0.1465875009074807,0.22480833251029253,-4.958676032075203,-17.455445150281538,-34.79445389295372,35.261303624789434,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-28,0.11500000208616257,0.11999999731779099,0.1120000034570694,0.1120000034570694,709740,0.0,0.0,0.11950000002980232,0.14513750094920397,0.22374166591713826,-6.276147758043922,-17.66428438668956,-35.13166161775384,33.875771409608376,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2023-12-29,0.11500000208616257,0.11699999868869781,0.10649999976158142,0.1080000028014183,181082,0.0,0.0,0.11790000051259994,0.14358750097453593,0.22239166585107645,-8.396944587055897,-17.889788656807575,-35.43485524736856,32.06654025087305,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-02,0.1145000010728836,0.1145000010728836,0.10849999636411667,0.10999999940395355,60976,0.0,0.0,0.1164000004529953,0.14232500083744526,0.22055833240350087,-5.49828266678246,-18.215352349837595,-35.47058536103342,33.96555898696076,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-03,0.10849999636411667,0.12950000166893005,0.10849999636411667,0.1264999955892563,358216,0.0,0.0,0.11695000007748604,0.14138750061392785,0.21898749905327955,8.165879012777106,-17.28406006919293,-35.43581198690783,47.103122343149536,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-04,0.1264999955892563,0.12950000166893005,0.12049999833106995,0.1289999932050705,230148,0.0,0.0,0.1181999996304512,0.14011250026524066,0.21744583224256833,9.13705043010588,-15.639218908596941,-35.564412147968724,48.7663067897905,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-05,0.12950000166893005,0.12950000166893005,0.12300000339746475,0.1274999976158142,18412,0.0,0.0,0.11879999935626984,0.13927500024437905,0.21619166557987532,7.323230897884023,-14.701131468090276,-35.57799748162735,47.79528165116748,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-08,0.12950000166893005,0.36000001430511475,0.12950000166893005,0.3100000023841858,16218416,0.0,0.0,0.13799999952316283,0.14262500032782555,0.21635833233594895,124.63768366329113,-3.242770057165355,-34.07926619328646,85.53471037861536,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-09,0.3179999887943268,0.46000000834465027,0.2800000011920929,0.2809999883174896,8228741,0.0,0.0,0.15404999852180482,0.14533750005066395,0.2162416656812032,82.4083031573128,5.994666530044707,-32.7893171776944,76.11812094726426,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-10,0.2809999883174896,0.3700000047683716,0.2370000034570694,0.27300000190734863,1817474,0.0,0.0,0.16919999867677687,0.14785000011324884,0.21618333235383033,61.34752011958412,14.440310143506633,-31.60897350251747,73.70744772748063,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-11,0.27000001072883606,0.2840000092983246,0.22100000083446503,0.23899999260902405,373048,0.0,0.0,0.18159999772906305,0.14983749985694886,0.2152333324154218,31.607927091275933,21.19796306160882,-30.383691886650933,64.37600534376281,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-12,0.2160000056028366,0.27799999713897705,0.20499999821186066,0.25699999928474426,886637,0.0,0.0,0.19609999731183053,0.15212499983608724,0.2146333324412505,31.055585317562716,28.907147098192798,-29.12331085493119,66.77423468811375,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-15,0.2290000021457672,0.2370000034570694,0.20999999344348907,0.23100000619888306,261426,0.0,0.0,0.208399997651577,0.15391249991953374,0.2139499992132187,10.84453397407946,35.40160660149735,-28.061462731697734,60.44443894321221,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-16,0.23100000619888306,0.23100000619888306,0.20999999344348907,0.20999999344348907,149270,0.0,0.0,0.21839999705553054,0.15516249984502792,0.21304999925196172,-3.846155551872865,40.75565763226457,-27.170851729726436,55.840191209223654,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-17,0.20999999344348907,0.21699999272823334,0.2029999941587448,0.21299999952316284,27709,0.0,0.0,0.2270499974489212,0.15648749992251396,0.2120666659126679,-6.1880634589829295,45.09145942094215,-26.208346206113433,56.3517044513919,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-18,0.21299999952316284,0.21299999952316284,0.19099999964237213,0.20000000298023224,223420,0.0,0.0,0.23414999842643738,0.15756249986588955,0.21083333268761634,-14.584666101090754,48.607694486781966,-25.266798253697452,53.461827932890316,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-19,0.20000000298023224,0.24899999797344208,0.19499999284744263,0.24899999797344208,109925,0.0,0.0,0.24629999846220016,0.15986249968409538,0.21024166606366634,1.0962239253348145,54.06990316610468,-23.962503400403474,61.480315087811825,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-22,0.25,0.2809999883174896,0.21299999952316284,0.257999986410141,352685,0.0,0.0,0.2410999968647957,0.16218749918043612,0.209799999371171,7.009535365038803,48.65510479113325,-22.6942327614122,62.74984178358519,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-23,0.25999999046325684,0.25999999046325684,0.2240000069141388,0.24300000071525574,68457,0.0,0.0,0.2372999981045723,0.16451249904930593,0.20919999939699968,2.4020238753527416,44.24435801285305,-21.36113789507719,59.24518305545681,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-24,0.25,0.25,0.20999999344348907,0.23899999260902405,164993,0.0,0.0,0.23389999717473983,0.1664874989539385,0.2084416658927997,2.1804170568134547,40.49102704068617,-20.127533887796684,58.309927470602304,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-25,0.24400000274181366,0.24400000274181366,0.20399999618530273,0.20600000023841858,61891,0.0,0.0,0.2305999979376793,0.1675499990582466,0.2075833326826493,-10.667822167938171,37.63055758509086,-19.28542773981047,51.13767027973256,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-26,0.20600000023841858,0.2750000059604645,0.1835000067949295,0.27399998903274536,968975,0.0,0.0,0.2322999969124794,0.17129999883472918,0.20706666596233844,17.95092237387188,35.61003998406516,-17.273020242724414,61.615075277913455,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-29,0.27399998903274536,0.3190000057220459,0.2199999988079071,0.2590000033378601,1489473,0.0,0.0,0.2350999966263771,0.17427499890327453,0.20644166606167952,10.165889857270013,34.90173467558674,-15.581480120778723,58.62862062107614,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-30,0.2590000033378601,0.2590000033378601,0.20399999618530273,0.22300000488758087,734957,0.0,0.0,0.2363999977707863,0.17609999887645245,0.2057583327094714,-5.668355757007271,34.24190759742076,-14.414159291860221,52.10158213001712,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-01-31,0.22300000488758087,0.22300000488758087,0.20100000500679016,0.2150000035762787,143453,0.0,0.0,0.23659999817609786,0.17783749885857106,0.2050499993065993,-9.129329994221989,33.04280576070118,-13.271153640600108,50.749477402626766,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-01,0.21799999475479126,0.21799999475479126,0.19949999451637268,0.20600000023841858,205715,0.0,0.0,0.2371999979019165,0.1795124989002943,0.20426666587591172,-13.153456129624125,32.13564479076372,-12.118554375707644,49.20250029103188,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-02,0.21699999272823334,0.21699999272823334,0.1899999976158142,0.20499999821186066,87633,0.0,0.0,0.23279999792575837,0.18127499893307686,0.20355833259721598,-11.94158073951673,28.42366531288935,-10.946903219251407,49.02368643342266,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-05,0.20499999821186066,0.20499999821186066,0.19099999964237213,0.20200000703334808,39099,0.0,0.0,0.22719999998807908,0.18283749893307685,0.20288333271940548,-11.091546195445954,24.263349320502368,-9.880473431522683,48.4547624404058,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-06,0.20200000703334808,0.21699999272823334,0.17100000381469727,0.1850000023841858,381627,0.0,0.0,0.22140000015497208,0.18399999886751175,0.20195833270748456,-16.44083005659783,20.326087781331996,-8.892098483494399,45.25010494406766,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-07,0.19949999451637268,0.19949999451637268,0.1809999942779541,0.18150000274181366,54670,0.0,0.0,0.21565000116825103,0.18531249910593034,0.20102083273231983,-15.835844303934596,16.370996132850617,-7.814281441817908,44.59615247110111,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-08,0.21699999272823334,0.21699999272823334,0.18199999630451202,0.18799999356269836,24511,0.0,0.0,0.213850000500679,0.18676249906420708,0.20021249937514465,-12.08791530393219,14.503715452618524,-6.717862447606665,46.152552199497855,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-09,0.18199999630451202,0.18700000643730164,0.17399999499320984,0.18199999630451202,28411,0.0,0.0,0.20465000122785568,0.18813749887049197,0.1993541660408179,-11.067678860224056,8.776826765795585,-5.626502517147955,44.89872349893349,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-12,0.17399999499320984,0.17900000512599945,0.16949999332427979,0.17350000143051147,138512,0.0,0.0,0.19610000103712083,0.18937499895691873,0.19848333274324734,-11.524732017890852,3.551156233527946,-4.588966569858489,43.11185935707892,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-13,0.18000000715255737,0.20100000500679016,0.17350000143051147,0.19750000536441803,87627,0.0,0.0,0.19355000108480452,0.19118749909102917,0.1978791660318772,2.0408185262074987,1.2356989892160837,-3.381693522889638,49.25295209043088,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-14,0.19750000536441803,0.19850000739097595,0.17949999868869781,0.19699999690055847,19404,0.0,0.0,0.1917500004172325,0.1930874990299344,0.1972458326568206,2.7379381861290226,-0.692690422436181,-2.1081984703428938,49.13394952665464,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-15,0.19699999690055847,0.19699999690055847,0.1889999955892563,0.18950000405311584,43239,0.0,0.0,0.19010000079870223,0.19491249918937684,0.19662499936918418,-0.3156216428540308,-2.4690558125771003,-0.870947328824623,47.28831352024157,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-16,0.18850000202655792,0.18950000405311584,0.17350000143051147,0.18950000405311584,69208,0.0,0.0,0.18855000138282776,0.19661249928176402,0.19625416609148186,0.503846546444312,-4.100704649190156,0.18258628462191934,47.28831352024157,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-19,0.1889999955892563,0.1889999955892563,0.16850000619888306,0.1850000023841858,46891,0.0,0.0,0.18685000091791154,0.19828749932348727,0.19597083280483882,-0.9900982203037322,-5.768138911730656,1.1821486317586596,46.083740062275396,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-20,0.1850000023841858,0.1965000033378601,0.16099999845027924,0.17149999737739563,73342,0.0,0.0,0.18550000041723252,0.19956249929964542,0.1957999994357427,-7.5471714330715045,-7.046664043477373,1.9216036132510308,42.579558830132974,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-21,0.16349999606609344,0.17800000309944153,0.16349999606609344,0.17749999463558197,47531,0.0,0.0,0.18509999960660933,0.20096249915659428,0.19553749933838843,-4.105891403122397,-7.893263477791719,2.7744038031383376,44.59598302732804,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-22,0.17599999904632568,0.17749999463558197,0.15049999952316284,0.16699999570846558,70719,0.0,0.0,0.18299999982118606,0.20226249899715185,0.1950874992956718,-8.74317165483852,-9.523514873727052,3.677836728331696,41.827749286426354,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-23,0.16699999570846558,0.19449999928474426,0.1509999930858612,0.1940000057220459,176556,0.0,0.0,0.18420000076293946,0.20431249905377627,0.19471249940494698,5.320306687576393,-9.843988196504354,4.930345857696587,50.360578978443556,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-26,0.1899999976158142,0.1899999976158142,0.17550000548362732,0.18400000035762787,41867,0.0,0.0,0.1852500006556511,0.20621249899268151,0.1941624994079272,-0.674763991146624,-10.165483876791768,6.206141567758543,47.577050213322046,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-27,0.17900000512599945,0.18299999833106995,0.15000000596046448,0.17000000178813934,117438,0.0,0.0,0.1825000002980232,0.20771249905228614,0.19368749943872293,-6.849314240806205,-12.138171207461305,7.2410453200157665,43.91728733316475,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-28,0.1509999930858612,0.16949999332427979,0.15000000596046448,0.16050000488758087,197757,0.0,0.0,0.17885000109672547,0.20856249928474427,0.19268333291014036,-10.259992226234637,-14.246328218119977,8.241068978191953,41.5799593846172,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-02-29,0.1599999964237213,0.1599999964237213,0.1550000011920929,0.15950000286102295,34304,0.0,0.0,0.17585000097751619,0.20932499952614309,0.1914124995470047,-9.297695777996449,-15.99187800043259,9.358061788822548,41.330604430145165,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-01,0.14149999618530273,0.15299999713897705,0.1379999965429306,0.14399999380111694,184039,0.0,0.0,0.1712999999523163,0.20973749943077563,0.1900208329161008,-15.93695630986496,-18.326479329055665,10.376055199894978,37.569738368280376,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-04,0.14399999380111694,0.15800000727176666,0.1120000034570694,0.15800000727176666,214024,0.0,0.0,0.16860000044107437,0.20593749955296517,0.1887041661888361,-6.287065920271099,-18.13050036682996,9.132460460297255,42.64618265383758,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-05,0.15800000727176666,0.15800000727176666,0.12399999797344208,0.1469999998807907,26313,0.0,0.0,0.1661500006914139,0.20258749984204769,0.18747083296378453,-11.525730202186386,-17.986055002921297,8.06347666955925,39.90084498645521,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-06,0.14100000262260437,0.15449999272823334,0.14100000262260437,0.1535000056028366,12450,0.0,0.0,0.16375000178813934,0.1995999999344349,0.18629166645308334,-6.25953958679294,-17.96092092087758,7.14381578883089,42.26596384708256,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-07,0.13199999928474426,0.14550000429153442,0.1315000057220459,0.14550000429153442,26759,0.0,0.0,0.16160000264644622,0.19726250022649766,0.185045833264788,-9.962870105971412,-18.078700989343442,6.60196814279436,40.17062531143317,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-08,0.13600000739097595,0.15399999916553497,0.13249999284744263,0.14949999749660492,131473,0.0,0.0,0.15715000182390212,0.19457500018179416,0.18381666665275892,-4.867963244359096,-19.23422758469759,5.852751942977184,41.72619920786292,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-11,0.14949999749660492,0.15049999952316284,0.14000000059604645,0.14000000059604645,132278,0.0,0.0,0.15275000184774398,0.19230000004172326,0.18281666673719882,-8.346972895231977,-20.5668217292762,5.1873461395928695,39.124405675492895,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-12,0.14000000059604645,0.14300000667572021,0.13349999487400055,0.1420000046491623,26976,0.0,0.0,0.1499500021338463,0.19060000032186508,0.18191666677594184,-5.301765502869273,-21.327386211633463,4.773247938089196,39.97300503708246,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-13,0.1315000057220459,0.15000000596046448,0.1315000057220459,0.13850000500679016,248385,0.0,0.0,0.14775000214576722,0.18873750045895576,0.18099583350121976,-6.260573268791697,-21.71666903160137,4.277262524766261,38.94974523080187,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-14,0.13650000095367432,0.1420000046491623,0.13249999284744263,0.14149999618530273,38260,0.0,0.0,0.1459500014781952,0.18727500028908253,0.18017500018080077,-3.0489929755549157,-22.066479106713118,3.9406133487759725,40.35903544619146,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-15,0.13349999487400055,0.15000000596046448,0.1315000057220459,0.13850000500679016,91136,0.0,0.0,0.1454000025987625,0.18451250046491624,0.17932916693389417,-4.745527832632292,-21.1977496199997,2.890401834595482,39.38005513130416,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-18,0.1315000057220459,0.14249999821186066,0.12800000607967377,0.14249999821186066,194219,0.0,0.0,0.1438500016927719,0.18162500075995922,0.17851666696369647,-0.9384799895897936,-20.798347644392763,1.7412008912842063,41.42039982681619,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-19,0.14399999380111694,0.20000000298023224,0.14000000059604645,0.16500000655651093,115046,0.0,0.0,0.14565000236034392,0.1796750009059906,0.17778333375851313,13.285275580218887,-18.936968623391966,1.0640295169888938,51.34140507140679,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-20,0.16500000655651093,0.19750000536441803,0.16500000655651093,0.19449999928474426,49001,0.0,0.0,0.1497500017285347,0.1785625010728836,0.17717083369692166,29.883136587425163,-16.13580632620538,0.7854946251156696,60.7316311926449,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-21,0.19850000739097595,0.20900000631809235,0.1679999977350235,0.19850000739097595,60974,0.0,0.0,0.15505000203847885,0.17837500125169753,0.17649166708191236,28.023221400354505,-13.076383489582009,1.0670952351031335,61.807882929161075,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-22,0.18150000274181366,0.18150000274181366,0.15950000286102295,0.16500000655651093,409728,0.0,0.0,0.15660000294446946,0.17565000168979167,0.17573333370188873,5.363986880013095,-10.845430436696285,-0.0474195818981207,49.55751449604,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-25,0.15399999916553497,0.20000000298023224,0.15000000596046448,0.16200000047683716,154363,0.0,0.0,0.15880000293254853,0.1732250016182661,0.17497500044604142,2.015111766495273,-8.327319123082336,-1.0001422050660236,48.62800520099298,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-26,0.16200000047683716,0.19750000536441803,0.16200000047683716,0.19349999725818634,89158,0.0,0.0,0.16395000219345093,0.17248750142753125,0.17475416709979374,18.023784488803013,-4.9496335464440895,-1.2970595836882748,57.61696317250353,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-27,0.19349999725818634,0.1979999989271164,0.1615000069141388,0.1979999989271164,119014,0.0,0.0,0.16990000158548355,0.17206250131130219,0.17457916711767515,16.539138951976177,-1.2568105829788914,-1.4415613546126096,58.727992100175264,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-03-28,0.1979999989271164,0.20100000500679016,0.17399999499320984,0.1979999989271164,102284,0.0,0.0,0.1755500018596649,0.17186250127851962,0.1745625004172325,12.788377573130457,2.145610912044934,-1.5467234556445113,58.727992100175264,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-02,0.1979999989271164,0.1979999989271164,0.18050000071525574,0.1835000067949295,129269,0.0,0.0,0.18005000203847885,0.17132500149309635,0.17442500044902165,1.9161370271539075,5.092660422789536,-1.7772675636777913,53.48818152757751,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-03,0.19699999690055847,0.19699999690055847,0.18250000476837158,0.18250000476837158,128483,0.0,0.0,0.18405000269412994,0.17083750143647194,0.17428333386778833,-0.842161316527811,7.733958379490365,-1.9771439728886504,53.13607207956013,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-04,0.18250000476837158,0.1965000033378601,0.18000000715255737,0.18000000715255737,188027,0.0,0.0,0.1855500027537346,0.17071250155568124,0.1741083338856697,-2.991105103104352,8.691514132146796,-1.9504134317995265,52.21072854169416,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-05,0.18000000715255737,0.19699999690055847,0.17000000178813934,0.17000000178813934,291071,0.0,0.0,0.18310000300407409,0.17042500153183937,0.173833333949248,-7.154560896235081,7.437289927127698,-1.960689782549825,48.567357942106526,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-08,0.16949999332427979,0.1965000033378601,0.164000004529953,0.17949999868869781,106407,0.0,0.0,0.1812000021338463,0.17021250165998936,0.17366250058015187,-0.9381917357223564,6.455166551635079,-1.9866113344200094,51.99457660789095,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-09,0.17949999868869781,0.17949999868869781,0.17949999868869781,0.17949999868869781,2606,0.0,0.0,0.18265000134706497,0.170150001719594,0.1734416672339042,-1.7246113523873614,7.346458713571385,-1.8978516332358881,51.994576607890956,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-10,0.15049999952316284,0.1704999953508377,0.15049999952316284,0.17000000178813934,6560,0.0,0.0,0.18345000147819518,0.1700625017285347,0.17317500052352747,-7.331697782327083,7.872105616222502,-1.7973141536499635,48.26464026076719,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-11,0.17000000178813934,0.17000000178813934,0.17000000178813934,0.17000000178813934,300,0.0,0.0,0.1811000019311905,0.16937500163912772,0.1729500005642573,-6.129210394635242,6.922509330535206,-2.067070779685448,48.26464026076719,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-12,0.17000000178813934,0.17000000178813934,0.16500000655651093,0.16500000655651093,7663,0.0,0.0,0.17780000269412993,0.16857500188052654,0.17272500060498713,-7.1990978310832165,5.472342109265635,-2.402662446041275,46.23987125649403,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-15,0.15950000286102295,0.16949999332427979,0.15950000286102295,0.16949999332427979,34343,0.0,0.0,0.1749500021338463,0.16807500161230565,0.17223750054836273,-3.1151807619853296,4.0904360884071425,-2.4167204719092448,48.34037746192659,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-16,0.16949999332427979,0.16949999332427979,0.15000000596046448,0.164000004529953,121123,0.0,0.0,0.17300000190734863,0.16743750162422658,0.17197916731238366,-5.202310565415853,3.322135261911488,-2.640823164300817,45.97593116722554,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-17,0.14149999618530273,0.16300000250339508,0.14149999618530273,0.16300000250339508,259529,0.0,0.0,0.171050001680851,0.1668875016272068,0.17182500064373016,-4.706225722508782,2.4941951991961484,-2.873562635254102,45.539782919787086,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-18,0.15950000286102295,0.16599999368190765,0.15950000286102295,0.16599999368190765,12102,0.0,0.0,0.16965000033378602,0.16675000153481961,0.17174583387871584,-2.1514922750940095,1.739129698515085,-2.908852128211855,47.15926529581791,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-19,0.15649999678134918,0.17000000178813934,0.15649999678134918,0.17000000178813934,25947,0.0,0.0,0.16965000033378602,0.16656250171363354,0.17183333386977515,0.20630795971983157,1.8536576890882277,-3.0674095866266162,49.323140109033616,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-22,0.17000000178813934,0.17000000178813934,0.1599999964237213,0.1599999964237213,78950,0.0,0.0,0.16770000010728836,0.16638750173151493,0.17174583387871584,-4.591534692093538,0.7888202912567918,-3.119919724506901,44.42516698019271,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-23,0.16750000417232513,0.16750000417232513,0.1535000056028366,0.16349999606609344,135173,0.0,0.0,0.16609999984502793,0.1656250014901161,0.17169166716436546,-1.5653243716798948,0.2867914569891627,-3.5334654118312874,46.430273992933884,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-24,0.16349999606609344,0.16349999606609344,0.16300000250339508,0.16300000250339508,10798,0.0,0.0,0.1653999999165535,0.1651000015437603,0.17163333383699259,-1.4510262481071594,0.1817070684361353,-3.806563764261117,46.17398037031409,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-25,0.1550000011920929,0.16949999332427979,0.1550000011920929,0.1550000011920929,56183,0.0,0.0,0.16389999985694886,0.16472500152885913,0.1715875004728635,-5.430139519599661,-0.5008357348630726,-3.999416580515823,42.16360842753128,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-26,0.16500000655651093,0.16500000655651093,0.14550000429153442,0.15950000286102295,57711,0.0,0.0,0.16334999948740006,0.1647000014781952,0.17155000045895577,-2.356900299025761,-0.8196733325311222,-3.993004350005512,45.054468166138676,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-29,0.15049999952316284,0.16949999332427979,0.15049999952316284,0.16300000250339508,66594,0.0,0.0,0.16270000040531157,0.1647875014692545,0.17140833375354608,0.18438973407262094,-1.2667836124285219,-3.8626081587206444,47.26240263759929,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-04-30,0.16949999332427979,0.17000000178813934,0.15049999952316284,0.17000000178813934,66444,0.0,0.0,0.16330000013113022,0.16543750166893006,0.17148333378136157,4.102879149803436,-1.292029628250412,-3.525609153446857,51.46327019622544,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-02,0.16099999845027924,0.17000000178813934,0.15850000083446503,0.1599999964237213,107542,0.0,0.0,0.16299999952316285,0.16548750139772891,0.1713500004261732,-1.8404927044280321,-1.5031357979039492,-3.4213592143935685,45.845058477873465,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-03,0.1599999964237213,0.17000000178813934,0.1599999964237213,0.16599999368190765,37608,0.0,0.0,0.16299999952316285,0.16596250124275685,0.17129583371182283,1.8404872193379926,-1.7850428243791578,-3.1135214170114813,49.41344068675749,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-06,0.16599999368190765,0.17299999296665192,0.1599999964237213,0.17299999296665192,55000,0.0,0.0,0.1632999986410141,0.16645000092685222,0.17130000032484533,5.939984327226798,-1.8924615610079867,-2.8312897774639767,53.28117647582203,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-07,0.1550000011920929,0.17800000309944153,0.1550000011920929,0.1599999964237213,29509,0.0,0.0,0.1632999986410141,0.1668125007301569,0.1713041669378678,-2.0208219502483016,-2.1056587928172,-2.6220414179066722,46.21429349112065,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-08,0.16099999845027924,0.1704999953508377,0.16099999845027924,0.1704999953508377,1750,0.0,0.0,0.16399999856948852,0.1673375006765127,0.17134583356479804,3.9634127061257693,-1.9944735002801646,-2.339323230039032,51.777607223675794,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-10,0.1704999953508377,0.1704999953508377,0.1615000069141388,0.1704999953508377,8741,0.0,0.0,0.16474999785423278,0.1681000005453825,0.17143750016887982,3.4901350965068927,-1.992862986484822,-1.9467733840085302,51.77760722367578,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-13,0.1704999953508377,0.1704999953508377,0.1655000001192093,0.1655000001192093,19268,0.0,0.0,0.16579999774694443,0.16868750043213368,0.1714833335330089,-0.1809394643014503,-1.7117466782021302,-1.6303818238622303,48.97970495139998,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-14,0.1655000001192093,0.17599999904632568,0.16099999845027924,0.16099999845027924,177246,0.0,0.0,0.16594999730587007,0.1692500002682209,0.1714916668832302,-2.982825511269675,-1.9497801814600393,-1.3071577504320733,46.54209475235967,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-15,0.1745000034570694,0.1745000034570694,0.16500000655651093,0.16500000655651093,75892,0.0,0.0,0.16614999771118164,0.1698375005275011,0.1715583335608244,-0.6921403373533223,-2.1711947036822785,-1.0030600074074445,48.973069342213925,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-16,0.16500000655651093,0.1720000058412552,0.1599999964237213,0.17149999737739563,128200,0.0,0.0,0.16629999727010727,0.17066250033676625,0.1716791668285926,3.1268792499391482,-2.5562165432069137,-0.5921897866858906,52.734469788591596,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-17,0.17149999737739563,0.17149999737739563,0.1599999964237213,0.1599999964237213,12991,0.0,0.0,0.16629999727010727,0.17110000029206276,0.17163750007748604,-3.788334906676753,-2.805378733934555,-0.31315987775435067,46.240077795284996,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-20,0.1599999964237213,0.16949999332427979,0.15000000596046448,0.15449999272823334,147580,0.0,0.0,0.16514999717473983,0.17083749994635583,0.17167499996721744,-6.448685818164482,-3.329188716412919,-0.4878404083422372,43.482019690116694,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-21,0.15449999272823334,0.15449999272823334,0.15449999272823334,0.15449999272823334,17944,0.0,0.0,0.163299997150898,0.16983749978244306,0.17162916660308838,-5.388857670666691,-3.8492692367229964,-1.0439174506910918,43.4820196901167,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-22,0.15000000596046448,0.15150000154972076,0.15000000596046448,0.15000000596046448,120655,0.0,0.0,0.1622999981045723,0.16862499974668027,0.17151666668554147,-7.578553473662243,-3.750927591762677,-1.6859393286617321,41.1528435800944,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-23,0.16750000417232513,0.16750000417232513,0.1445000022649765,0.15000000596046448,36005,0.0,0.0,0.16024999916553498,0.1682499997317791,0.17173333341876665,-6.396251643335403,-4.7548294674576885,-2.0283387142399136,41.15284358009439,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-24,0.14499999582767487,0.16750000417232513,0.14499999582767487,0.14749999344348907,76143,0.0,0.0,0.1579499989748001,0.1678874995559454,0.17179583335916201,-6.616021272009166,-5.919142644586114,-2.2749875400328987,39.779887996271036,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-27,0.14749999344348907,0.15150000154972076,0.1404999941587448,0.15150000154972076,140053,0.0,0.0,0.15654999911785125,0.16683749966323375,0.1718083333224058,-3.225804916376165,-6.166180005183551,-2.8932436297161868,43.05349887679956,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-28,0.15150000154972076,0.16699999570846558,0.11550000309944153,0.14949999749660492,156965,0.0,0.0,0.15539999902248383,0.16562499962747096,0.17184166659911473,-3.796654802440043,-6.173585284821449,-3.6176714848480183,41.829111553195865,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-29,0.1550000011920929,0.16699999570846558,0.1354999989271164,0.14000000059604645,419244,0.0,0.0,0.15289999842643737,0.16417499966919422,0.17184999994933606,-8.43688552200824,-6.867672462601192,-4.466104324937181,36.51683395969506,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-30,0.11100000143051147,0.14949999749660492,0.10000000149011612,0.13699999451637268,919127,0.0,0.0,0.14944999814033508,0.1630124993622303,0.17187083326280117,-8.330547861413633,-8.319914899137872,-5.15406467310595,35.00496175460128,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-05-31,0.13699999451637268,0.13850000500679016,0.12349999696016312,0.13850000500679016,57901,0.0,0.0,0.14729999899864196,0.16191249936819077,0.17186249991257985,-5.974198269976181,-9.024936571647766,-5.789512284209922,36.42233229884496,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-03,0.14800000190734863,0.14800000190734863,0.1289999932050705,0.1469999998807907,26824,0.0,0.0,0.1465499997138977,0.1610874991863966,0.17193333320319654,0.307062550509395,-9.024598150646899,-6.308162480617985,43.88950734309839,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-04,0.1459999978542328,0.1459999978542328,0.1459999978542328,0.1459999978542328,250,0.0,0.0,0.14570000022649765,0.16048749908804893,0.17207499990860622,0.20590091096003926,-9.214112591684389,-6.733982755607573,43.245983827851234,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-05,0.13199999928474426,0.14499999582767487,0.13099999725818634,0.1340000033378601,345345,0.0,0.0,0.14409999996423722,0.159349999204278,0.17210833330949146,-7.009019173409949,-9.570128218507936,-7.412967088741112,36.35698078185059,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-07,0.1340000033378601,0.1379999965429306,0.12300000339746475,0.1379999965429306,28305,0.0,0.0,0.14289999902248382,0.1583124991506338,0.17219999991357327,-3.4289730672302197,-9.735491645220662,-8.064750737461997,39.79947907696899,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-10,0.1379999965429306,0.1469999998807907,0.12600000202655792,0.1469999998807907,34007,0.0,0.0,0.14284999966621398,0.1577374991029501,0.1723916665961345,2.905145414262304,-9.438148519788268,-8.500508048057233,46.775427226024696,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-11,0.1469999998807907,0.1469999998807907,0.12600000202655792,0.1420000046491623,227071,0.0,0.0,0.14189999997615815,0.15703749917447568,0.1725333333015442,0.07047545667437768,-9.63941687679265,-8.981356721362213,43.742785979466476,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-12,0.12200000137090683,0.13899999856948853,0.12200000137090683,0.13600000739097595,71594,0.0,0.0,0.14055000096559525,0.1563124991953373,0.17265833336859943,-3.2372775121738173,-10.083965332832596,-9.4671562352952,40.36110620168592,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-13,0.15000000596046448,0.1509999930858612,0.1420000046491623,0.1420000046491623,187236,0.0,0.0,0.14075000137090682,0.15562499947845937,0.17287083342671394,0.8881017876237484,-9.558231747728586,-9.976138603835501,44.94473638378349,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-14,0.13300000131130219,0.1379999965429306,0.12999999523162842,0.13699999451637268,324633,0.0,0.0,0.14075000137090682,0.15494999922811986,0.17300000004470348,-2.6643032454771034,-9.164245193901278,-10.433526480878305,42.04474798429466,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-17,0.13699999451637268,0.14000000059604645,0.12700000405311584,0.12800000607967377,112904,0.0,0.0,0.1397000014781952,0.15407499931752683,0.1730833334227403,-8.375086095004516,-9.329870454652276,-10.982186285254478,37.370592480147025,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-18,0.12999999523162842,0.13600000739097595,0.11999999731779099,0.12600000202655792,115293,0.0,0.0,0.13760000169277192,0.15307499952614306,0.17312916678686938,-8.43023221185276,-10.109422101110788,-11.583355729663964,36.40211043489827,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-19,0.11800000071525574,0.1340000033378601,0.11800000071525574,0.1289999932050705,73119,0.0,0.0,0.13590000122785567,0.15204999931156635,0.17319166672726471,-5.0772685507311595,-10.621504871313837,-12.207092763297565,38.95755969863133,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-20,0.12999999523162842,0.13099999725818634,0.12300000339746475,0.12800000607967377,66165,0.0,0.0,0.13530000150203705,0.15124999955296517,0.1733000000938773,-5.395414147318675,-10.545453287980141,-12.723600997673145,38.40362836611893,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-24,0.12999999523162842,0.14000000059604645,0.12600000202655792,0.12600000202655792,50221,0.0,0.0,0.1341000020503998,0.15031249970197677,0.17341666674862305,-6.040268381798821,-10.785861244887386,-13.322921885090222,37.26244180741601,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-25,0.14300000667572021,0.14300000667572021,0.125,0.1420000046491623,34436,0.0,0.0,0.13360000252723694,0.14978749975562095,0.17370000009735426,6.28742661903232,-10.806974717378942,-13.766551714640753,50.05014347823392,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-26,0.125,0.13899999856948853,0.125,0.125,25857,0.0,0.0,0.13190000206232072,0.14903749972581865,0.1738250001023213,-5.231237266441115,-11.498782316548144,-14.26003184922284,40.584701279673254,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-27,0.12600000202655792,0.1289999932050705,0.125,0.1289999932050705,47652,0.0,0.0,0.13120000064373016,0.14827499948441983,0.17384583341578644,-1.6768349297754388,-11.515763884716007,-14.708913885907718,43.30176615726039,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-06-28,0.1289999932050705,0.13500000536441803,0.1289999932050705,0.12999999523162842,220813,0.0,0.0,0.1299999997019768,0.14744999930262565,0.17385416676600773,-3.4387295226959536e-06,-11.834519961464744,-15.187537897161679,43.9913438218123,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-01,0.16200000047683716,0.16200000047683716,0.11999999731779099,0.12999999523162842,199320,0.0,0.0,0.12929999977350234,0.14644999913871287,0.17387500007947285,0.5413731317496296,-11.710481028386067,-15.77282583938166,43.99134382181229,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-02,0.12999999523162842,0.1550000011920929,0.11999999731779099,0.1550000011920929,43901,0.0,0.0,0.13199999928474426,0.14632499925792217,0.17258333340287207,17.424243963618586,-9.789851389595915,-15.21487250663622,58.59284844284125,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-03,0.1599999964237213,0.1599999964237213,0.10899999737739563,0.1469999998807907,85640,0.0,0.0,0.13409999907016754,0.14584999941289425,0.17146666683256626,9.619687472088106,-8.056222413455785,-14.939736039008771,53.762723674798174,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-04,0.11900000274181366,0.14900000393390656,0.11900000274181366,0.14100000262260437,78578,0.0,0.0,0.13530000001192094,0.14504999965429305,0.17036666683852672,4.212862239601787,-6.721819831513208,-14.860105943276317,50.40653578246431,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-05,0.13199999928474426,0.14399999380111694,0.13199999928474426,0.13899999856948853,48219,0.0,0.0,0.1363999992609024,0.14452499970793725,0.16953333355486394,1.9061578611983048,-5.621865049959675,-14.751278301758608,49.30171573916308,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-08,0.1379999965429306,0.1379999965429306,0.12999999523162842,0.1379999965429306,50011,0.0,0.0,0.13759999871253967,0.14371249973773956,0.16854166686534883,0.2906961003877418,-4.253284186382237,-14.731767870461235,48.72663895343178,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-09,0.1379999965429306,0.1459999978542328,0.1340000033378601,0.14300000667572021,54079,0.0,0.0,0.13769999891519547,0.14302500002086163,0.16780833353598912,3.84895265234449,-3.7231261002548233,-14.768833581088101,51.756727046867006,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-10,0.13500000536441803,0.13899999856948853,0.12600000202655792,0.13500000536441803,29519,0.0,0.0,0.13869999945163727,0.14226250015199185,0.1671833336353302,-2.6676237215915632,-2.5041741123264636,-14.906290562250113,46.97350750187652,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-11,0.14000000059604645,0.15600000321865082,0.1340000033378601,0.15600000321865082,108700,0.0,0.0,0.1414000004529953,0.14213750027120114,0.16670833366612595,10.325320168940804,-0.518863647382763,-14.738815303699143,57.957413590688546,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-12,0.15600000321865082,0.15800000727176666,0.13899999856948853,0.15600000321865082,72583,0.0,0.0,0.14400000125169754,0.14191250018775464,0.1663416670014461,8.333334626836898,1.4709775820883075,-14.686138027869514,57.957413590688546,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-15,0.17800000309944153,0.17800000309944153,0.12800000607967377,0.16200000047683716,47109,0.0,0.0,0.14720000177621842,0.14167500026524066,0.1656166670223077,10.054346822032322,3.899771660938049,-14.456073285089255,60.657787237224426,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-16,0.16200000047683716,0.17499999701976776,0.13199999928474426,0.1420000046491623,471698,0.0,0.0,0.14590000212192536,0.1412250004708767,0.1646500005076329,-2.6730619712424177,3.3103215687457173,-14.2271484752715,49.29253400612836,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-17,0.14499999582767487,0.1550000011920929,0.13899999856948853,0.1459999978542328,64046,0.0,0.0,0.14580000191926956,0.14101250059902667,0.1638416671504577,0.1371714213515343,3.395090009683817,-13.933675693416092,51.25949875323668,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-18,0.13199999928474426,0.14000000059604645,0.13199999928474426,0.14000000059604645,11000,0.0,0.0,0.14570000171661376,0.140650000795722,0.16301666721701621,-3.912148972828297,3.590473439261687,-13.720478281842519,48.236899733336536,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-19,0.14000000059604645,0.14000000059604645,0.13500000536441803,0.13899999856948853,15859,0.0,0.0,0.14570000171661376,0.1403750006109476,0.16245833386977512,-4.598492153868833,3.793411278710889,-13.593228942338712,47.731717860565375,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-22,0.13899999856948853,0.13899999856948853,0.13099999725818634,0.13500000536441803,25588,0.0,0.0,0.1454000025987625,0.14000000059604645,0.16130000067253908,-7.152680225903239,3.8571442712326376,-13.205207679902326,45.67130228801371,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-23,0.1340000033378601,0.1340000033378601,0.13199999928474426,0.1340000033378601,39804,0.0,0.0,0.1445000022649765,0.13966250084340573,0.16025833400587242,-7.266435129780863,3.463708148112528,-12.851645619697996,45.14661652904882,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-24,0.13300000131130219,0.1340000033378601,0.13300000131130219,0.1340000033378601,41970,0.0,0.0,0.1444000020623207,0.1392250008881092,0.1595166673262914,-7.202215080282426,3.7170056679478694,-12.720718642319417,45.14661652904882,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-25,0.13099999725818634,0.14499999582767487,0.12999999523162842,0.12999999523162842,67028,0.0,0.0,0.14180000126361847,0.13873750083148478,0.1588083339234193,-8.321583869419591,2.207406370865438,-12.638400388743515,42.86227788396145,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-26,0.1289999932050705,0.12999999523162842,0.1289999932050705,0.12999999523162842,65389,0.0,0.0,0.13920000046491623,0.13848750069737434,0.15817500054836273,-6.609199139770529,0.514486696600053,-12.446657046142287,42.86227788396145,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-29,0.14000000059604645,0.14000000059604645,0.12999999523162842,0.12999999523162842,1050,0.0,0.0,0.13599999994039536,0.13831250071525575,0.15755000052352747,-4.411768170144526,-1.6719390965399026,-12.210409231575293,42.86227788396145,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-30,0.13899999856948853,0.13899999856948853,0.1379999965429306,0.1379999965429306,14158,0.0,0.0,0.1355999991297722,0.13830000050365926,0.15701666710277398,1.76990960808308,-1.9522786435677768,-11.920178248888623,49.273665014064754,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-07-31,0.13699999451637268,0.13699999451637268,0.13699999451637268,0.13699999451637268,211869,0.0,0.0,0.13469999879598618,0.1380500003695488,0.15661666703720886,1.707494982141778,-2.4266581416841144,-11.854847264275534,48.5404549352851,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-01,0.15700000524520874,0.15700000524520874,0.1379999965429306,0.1379999965429306,17500,0.0,0.0,0.13449999839067459,0.13785000033676625,0.15625416698555153,2.602229140620336,-2.4301791352249875,-11.778352541783455,49.35208810598791,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-02,0.12200000137090683,0.13699999451637268,0.12200000137090683,0.13600000739097595,59773,0.0,0.0,0.13419999927282333,0.13790000043809414,0.15582083376745384,1.3412877257124813,-2.6831045348196385,-11.500922499301126,47.730641831794266,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-05,0.13600000739097595,0.13600000739097595,0.11400000005960464,0.11400000005960464,118903,0.0,0.0,0.132099998742342,0.137300000526011,0.1552541671320796,-13.701740238499907,-3.787328305715395,-11.564370179381035,34.35827568336225,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-06,0.11999999731779099,0.12800000607967377,0.11999999731779099,0.12800000607967377,65605,0.0,0.0,0.13149999901652337,0.13682500068098308,0.15487500050415595,-2.661591606863678,-3.8918338300434683,-11.654559977023869,44.931435996263055,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-07,0.12800000607967377,0.12800000607967377,0.12800000607967377,0.12800000607967377,360,0.0,0.0,0.13089999929070473,0.13647500071674584,0.15429583384344975,-2.2154264528226704,-4.084998275700355,-11.549782442463819,44.931435996263055,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-08,0.14399999380111694,0.14399999380111694,0.14300000667572021,0.14300000667572021,14730,0.0,0.0,0.1322000004351139,0.13665000069886446,0.15384583392490944,8.169444935748807,-3.2564948708321064,-11.17731484002231,54.11529488156637,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-09,0.14300000667572021,0.14300000667572021,0.12999999523162842,0.14000000059604645,10467,0.0,0.0,0.1332000009715557,0.13660000059753657,0.15343333389610053,5.105104785954805,-2.489018748981016,-10.971105737663809,52.23887173931982,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-12,0.14000000059604645,0.14000000059604645,0.12999999523162842,0.13899999856948853,17767,0.0,0.0,0.13410000130534172,0.13665000069886446,0.1530125005170703,3.653987484302596,-1.8660807760566147,-10.693570631753982,51.59663439679226,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-13,0.14100000262260437,0.14100000262260437,0.12800000607967377,0.12800000607967377,55070,0.0,0.0,0.13310000225901603,0.13665000069886446,0.15253750054786602,-3.8317025490484475,-2.5978766349746047,-10.415471468942872,45.037424821152115,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-14,0.12800000607967377,0.14000000059604645,0.12800000607967377,0.14000000059604645,10714,0.0,0.0,0.13340000286698342,0.13700000066310167,0.15227500057468812,4.947524428199642,-2.627735604885905,-10.031193468355527,52.1794022918204,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-15,0.1379999965429306,0.1379999965429306,0.1379999965429306,0.1379999965429306,2898,0.0,0.0,0.13340000286698342,0.13722500074654817,0.15194583392391603,3.4482710472907234,-2.787391407364206,-9.688211119193326,50.99015479712585,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-16,0.12800000607967377,0.13699999451637268,0.12800000607967377,0.13699999451637268,12454,0.0,0.0,0.13350000157952308,0.13745000045746564,0.15169583391398192,2.6217175246733873,-2.873771454926188,-9.391051216735645,50.37197218155747,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-19,0.13300000131130219,0.13699999451637268,0.13300000131130219,0.13699999451637268,49,0.0,0.0,0.1358000010251999,0.13772500026971102,0.1512208338206013,0.8836476304224041,-1.3977122822590904,-8.924586123431167,50.37197218155747,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-20,0.14000000059604645,0.14000000059604645,0.13899999856948853,0.13899999856948853,7391,0.0,0.0,0.13690000027418137,0.13765000011771916,0.15084583380570013,1.5339651505488041,-0.5448600384281814,-8.747894028666456,51.7293871455272,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-21,0.12800000607967377,0.14000000059604645,0.12800000607967377,0.14000000059604645,565,0.0,0.0,0.13809999972581863,0.13802500013262034,0.15059583379576605,1.3758152599565883,0.05433768746692663,-8.34739802974492,52.42999261278529,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-22,0.14000000059604645,0.14000000059604645,0.14000000059604645,0.14000000059604645,36214,0.0,0.0,0.13779999911785126,0.13830000031739473,0.15042500042666992,1.5965177737872613,-0.36153376601299775,-8.060495313201589,52.42999261278529,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-23,0.14000000059604645,0.14000000059604645,0.11999999731779099,0.12999999523162842,5550,0.0,0.0,0.13679999858140945,0.13830000031739473,0.15017916702975828,-4.970762734134362,-1.0845999512240134,-7.909996404501081,44.876044477251945,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-26,0.12999999523162842,0.13199999928474426,0.12999999523162842,0.13199999928474426,12561,0.0,0.0,0.13609999865293504,0.13835000041872264,0.15007916707545518,-3.012490381168978,-1.6263113545196008,-7.815319664477801,46.53516434708786,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-27,0.13199999928474426,0.13199999928474426,0.12099999934434891,0.12099999934434891,5622,0.0,0.0,0.13539999797940255,0.13750000037252902,0.14977083367606003,-10.635154246637594,-1.527274463590491,-8.19307271138762,39.49440560184076,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-28,0.14300000667572021,0.14300000667572021,0.12099999934434891,0.12099999934434891,38031,0.0,0.0,0.13349999785423278,0.13685000035911798,0.14955416700492302,-9.363294914455718,-2.447937519981165,-8.494692525275369,39.49440560184076,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-29,0.13899999856948853,0.13899999856948853,0.12700000405311584,0.12700000405311584,12712,0.0,0.0,0.1323999986052513,0.13650000039488078,0.14933333365867535,-4.078545777206141,-3.003664306057562,-8.593749934711267,44.77965629515067,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-08-30,0.1289999932050705,0.1289999932050705,0.1289999932050705,0.1289999932050705,3295,0.0,0.0,0.1315999984741211,0.13625000026077033,0.14919583356628816,-1.975687917323107,-3.4128453414675555,-8.677074282886025,46.458541454411645,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-02,0.1289999932050705,0.1289999932050705,0.1289999932050705,0.1289999932050705,11000,0.0,0.0,0.1307999983429909,0.13602500017732383,0.14902500019719203,-1.3761507344979618,-3.84120700424302,-8.723368564110997,46.458541454411645,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-03,0.1340000033378601,0.1340000033378601,0.1340000033378601,0.1340000033378601,6888,0.0,0.0,0.13029999881982804,0.13580000009387733,0.14897500022004048,2.839604414078498,-4.050074573083347,-8.843765804130419,50.79599603968656,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-04,0.125,0.125,0.11999999731779099,0.11999999731779099,26488,0.0,0.0,0.1282999984920025,0.13542499989271164,0.14879166682561237,-6.469213773785729,-5.261215732954642,-8.983478186696303,40.82362682181956,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-05,0.11999999731779099,0.11999999731779099,0.11500000208616257,0.11500000208616257,24333,0.0,0.0,0.1257999986410141,0.13439999986439943,0.1485958334679405,-8.585052998029564,-6.398810440522438,-9.553318738646743,37.957517688904815,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-06,0.11699999868869781,0.1340000033378601,0.11699999868869781,0.12800000607967377,10100,0.0,0.0,0.12559999972581865,0.13369999993592502,0.1484833335503936,1.9108330884508518,-6.058339726244019,-9.956224217885888,48.150166929784284,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-09,0.11400000005960464,0.12099999934434891,0.11400000005960464,0.12099999934434891,11454,0.0,0.0,0.1244999997317791,0.1326749999076128,0.14833750016987324,-2.811245297165089,-6.161673398550072,-10.558692336276424,43.962078997801406,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-10,0.11400000005960464,0.11400000005960464,0.11400000005960464,0.11400000005960464,4257,0.0,0.0,0.12379999980330467,0.13197499979287386,0.1481000001852711,-7.915993343514065,-6.19435499329367,-10.887913823244494,40.19682747130292,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-11,0.10000000149011612,0.1420000046491623,0.10000000149011612,0.10599999874830246,9780,0.0,0.0,0.12229999974370002,0.1309749998152256,0.14760833345353602,-13.327883098574755,-6.623401476437424,-11.268560012261268,36.36364154541523,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-12,0.10599999874830246,0.14800000190734863,0.10599999874830246,0.1420000046491623,56522,0.0,0.0,0.12379999980330467,0.1310249999165535,0.1471708334982395,14.701134793840124,-5.5142149344401865,-10.970810722410661,56.47698523737663,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-13,0.1420000046491623,0.1420000046491623,0.11299999803304672,0.12099999934434891,10127,0.0,0.0,0.12300000041723251,0.130574999935925,0.14652500009785097,-1.6260171269100252,-5.801263275825885,-10.885514520576272,47.12090218902378,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-16,0.14000000059604645,0.14000000059604645,0.10100000351667404,0.1379999965429306,12377,0.0,0.0,0.12390000075101852,0.13064999971538782,0.14630000001440446,11.380141813111468,-5.16647453430824,-10.69719774263552,53.79410169456162,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-17,0.1420000046491623,0.1420000046491623,0.11100000143051147,0.13899999856948853,12566,0.0,0.0,0.12440000027418137,0.13077499959617853,0.14610833333184323,11.736333008945593,-4.874784432561715,-10.494496368553753,54.16056127251266,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-18,0.1379999965429306,0.1379999965429306,0.12999999523162842,0.12999999523162842,40057,0.0,0.0,0.12540000006556512,0.13067499939352273,0.14557916664828857,3.6682577062665076,-4.036731855702674,-10.23784350323526,50.29444300125268,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-19,0.14100000262260437,0.14100000262260437,0.13099999725818634,0.13099999725818634,6780,0.0,0.0,0.12699999958276748,0.1306999994441867,0.14502083330104748,3.149604479181133,-2.830910388028921,-9.875018320390069,50.71540804822365,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-20,0.13899999856948853,0.13899999856948853,0.13899999856948853,0.13899999856948853,5797,0.0,0.0,0.12809999883174897,0.1309249995276332,0.14452916663140059,8.508977234305833,-2.1577244270205136,-9.412748596594845,54.06691819668303,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-23,0.13899999856948853,0.13899999856948853,0.13899999856948853,0.13899999856948853,22213,0.0,0.0,0.12989999875426292,0.1311499996110797,0.1441583332295219,7.005388685522965,-0.9531077853782806,-9.023643189416571,54.06691819668303,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-24,0.10999999940395355,0.13899999856948853,0.10999999940395355,0.13899999856948853,26295,0.0,0.0,0.1323999986052513,0.13117499966174365,0.14379583317786454,4.984894285320212,0.9338661686041756,-8.776911845915507,54.06691819668303,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-25,0.11299999803304672,0.11599999666213989,0.11299999803304672,0.11599999666213989,28457,0.0,0.0,0.13339999839663505,0.13064999971538782,0.14326249975711108,-13.043479717863374,2.104859309022514,-8.803769348647862,43.45564613896513,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-26,0.11999999731779099,0.11999999731779099,0.11999999731779099,0.11999999731779099,41416,0.0,0.0,0.13119999766349794,0.13019999973475932,0.1428458330531915,-8.536585781375345,0.7680475658800237,-8.85278418567748,45.46041601779001,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-27,0.1379999965429306,0.1379999965429306,0.12399999797344208,0.12999999523162842,82551,0.0,0.0,0.13209999725222588,0.13004999943077564,0.1424333330243826,-1.589706331778196,1.576315132966558,-8.694126108449005,50.21285985770706,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-09-30,0.12999999523162842,0.12999999523162842,0.12999999523162842,0.12999999523162842,11336,0.0,0.0,0.13129999712109566,0.13044999931007623,0.1420208329955737,-0.9901004706559713,0.6515889731812223,-8.147279129012071,50.21285985770706,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-01,0.12800000607967377,0.12800000607967377,0.11500000208616257,0.11500000208616257,201082,0.0,0.0,0.12889999747276307,0.13012499921023846,0.14156249966472387,-10.783549774341623,-0.9414038385477311,-8.079470538860184,43.603134676368676,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-02,0.10999999940395355,0.10999999940395355,0.10000000149011612,0.10199999809265137,139143,0.0,0.0,0.12609999775886535,0.1294749990105629,0.14099583296726148,-19.111816094001203,-2.6066818130828477,-8.171045706984595,38.83225792147594,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-03,0.10999999940395355,0.11400000005960464,0.10000000149011612,0.10000000149011612,91705,0.0,0.0,0.12299999818205834,0.1283999988809228,0.14045416625837484,-18.69918457876625,-4.205608057576679,-8.58227826099341,38.140839120762514,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-04,0.11100000143051147,0.11100000143051147,0.10000000149011612,0.10999999940395355,21000,0.0,0.0,0.12009999826550484,0.12764999885112047,0.13995833297570545,-8.409657791354201,-5.914610774435864,-8.794284600918703,43.55270483789804,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-07,0.10000000149011612,0.11699999868869781,0.10000000149011612,0.10000000149011612,572577,0.0,0.0,0.1161999985575676,0.12667499892413617,0.13942499961704016,-13.941477855893181,-8.269193175870395,-9.144701974484153,39.80263390108684,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-08,0.10000000149011612,0.11999999731779099,0.10000000149011612,0.11500000208616257,78601,0.0,0.0,0.113799998909235,0.12634999882429837,0.1390249996135632,1.054484348356333,-9.932726578427062,-9.117065869085803,47.15317487190802,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-09,0.11500000208616257,0.11500000208616257,0.1080000028014183,0.11500000208616257,67760,0.0,0.0,0.11369999945163727,0.12572499886155128,0.13859999968359868,1.1433620411566168,-9.564525367907123,-9.289322403635598,47.15317487190802,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-10,0.11999999731779099,0.11999999731779099,0.11999999731779099,0.11999999731779099,60833,0.0,0.0,0.11369999945163727,0.1252749988809228,0.1381833329796791,5.540895247614709,-9.23967234698432,-9.341455167139854,49.535366098440555,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-11,0.11900000274181366,0.11999999731779099,0.11900000274181366,0.11999999731779099,41666,0.0,0.0,0.11269999966025353,0.12484999895095825,0.13784999965379635,6.477371499151818,-9.731677527267985,-9.430540976051493,49.535366098440555,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-14,0.10000000149011612,0.10000000149011612,0.09600000083446503,0.10000000149011612,133314,0.0,0.0,0.1097000002861023,0.12392499912530183,0.13732083303232986,-8.842296053498787,-11.478716110230906,-9.755135918724154,40.96824736051015,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-15,0.10000000149011612,0.10000000149011612,0.09600000083446503,0.10000000149011612,56869,0.0,0.0,0.10820000022649764,0.12294999919831753,0.1367958330238859,-7.57855704178953,-11.996745886942414,-10.1215318621224,40.96824736051015,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-16,0.10000000149011612,0.11599999666213989,0.09600000083446503,0.11599999666213989,7661,0.0,0.0,0.1096000000834465,0.12234999909996987,0.13647083298613627,5.839412932318069,-10.420922852729717,-10.34714420450625,49.13092365923203,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-17,0.11599999666213989,0.11599999666213989,0.10300000011920929,0.11299999803304672,37550,0.0,0.0,0.11089999973773956,0.12167499903589488,0.13608333294590313,1.8935963032221041,-8.855557331853047,-10.587875530456008,47.79639493526939,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-18,0.11299999803304672,0.11299999803304672,0.10000000149011612,0.11299999803304672,99423,0.0,0.0,0.11119999960064889,0.12124999910593033,0.13566666624198356,1.6187036320702768,-8.288659446917803,-10.626536005785505,47.79639493526939,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-21,0.1120000034570694,0.1120000034570694,0.1120000034570694,0.1120000034570694,53196,0.0,0.0,0.1123999997973442,0.12074999921023846,0.135183332922558,-0.35586863077935627,-6.915113430647754,-10.676858899897004,47.29971402684318,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-22,0.11299999803304672,0.11999999731779099,0.11299999803304672,0.11999999731779099,16804,0.0,0.0,0.11289999932050705,0.1207249991595745,0.13484999959667524,6.288749371138655,-6.481673136087046,-10.474601764440038,51.63016956016158,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-23,0.11900000274181366,0.11999999731779099,0.11900000274181366,0.11999999731779099,92733,0.0,0.0,0.11339999884366989,0.12069999910891056,0.13446666629364093,5.820104533880706,-6.048053288429363,-10.237977607526517,51.63016956016158,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-24,0.11999999731779099,0.11999999731779099,0.10700000077486038,0.10700000077486038,55945,0.0,0.0,0.11209999918937683,0.12019999902695418,0.13391666635870933,-4.549507985188055,-6.738768638226837,-10.242688759152406,44.70680507393238,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-25,0.11999999731779099,0.11999999731779099,0.11999999731779099,0.11999999731779099,5495,0.0,0.0,0.11209999918937683,0.11997499912977219,0.13358333303282657,7.047277596379148,-6.563867470319622,-10.18714954485399,51.68411854551636,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-28,0.11100000143051147,0.11999999731779099,0.11100000143051147,0.11999999731779099,16522,0.0,0.0,0.11409999877214431,0.11974999923259019,0.13316249971588454,5.170901497929779,-4.718163253990418,-10.072280493315496,51.68411854551636,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-29,0.11999999731779099,0.11999999731779099,0.11999999731779099,0.11999999731779099,155632,0.0,0.0,0.1160999983549118,0.11939999908208847,0.13274166639894247,3.3591722809134605,-2.7638197257504884,-10.05085115984373,51.68411854551638,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-30,0.11999999731779099,0.14499999582767487,0.11100000143051147,0.14499999582767487,69969,0.0,0.0,0.1189999982714653,0.12002499904483557,0.13257083302984635,21.848737759556787,-0.8539894034803347,-9.463494871595373,62.921984111633435,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-10-31,0.1445000022649765,0.1459999978542328,0.1445000022649765,0.1459999978542328,36000,0.0,0.0,0.12229999825358391,0.12079999893903733,0.1324458330248793,19.378577219198256,1.2417212977821064,-8.7929033476307,63.28979645426388,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-01,0.14800000190734863,0.1599999964237213,0.14800000190734863,0.1599999964237213,16889,0.0,0.0,0.12699999809265136,0.12159999869763852,0.13240416627377272,25.984251044630085,4.44078902372366,-8.159990640924676,68.06592443568451,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-04,0.1599999964237213,0.1599999964237213,0.1599999964237213,0.1599999964237213,36760,0.0,0.0,0.13179999738931655,0.12257499862462282,0.13230833293249208,21.39605431941427,7.526003563699509,-7.356554263921929,68.06592443568451,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-05,0.1599999964237213,0.1599999964237213,0.1599999964237213,0.1599999964237213,13709,0.0,0.0,0.1357999972999096,0.12372499853372573,0.13230833293249208,17.82032371500483,9.759546501746282,-6.487372494630282,68.06592443568451,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-06,0.11100000143051147,0.13449999690055847,0.10100000351667404,0.10100000351667404,99462,0.0,0.0,0.1338999979197979,0.12359999865293503,0.13186249968906244,-24.570571257835248,8.333332831001842,-6.265997577484692,40.39987295376361,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-07,0.10000000149011612,0.14000000059604645,0.10000000149011612,0.13500000536441803,91899,0.0,0.0,0.13669999837875366,0.12342499867081642,0.13169999979436398,-1.2435940266988659,10.755519425479303,-6.283220301038813,52.40552249296153,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-08,0.12999999523162842,0.12999999523162842,0.11999999731779099,0.12999999523162842,74000,0.0,0.0,0.1376999981701374,0.12364999856799841,0.13153333303829035,-5.591868584482562,11.362717157180166,-5.993411926995751,50.7853778422873,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-11,0.13899999856948853,0.13899999856948853,0.13899999856948853,0.13899999856948853,8097,0.0,0.0,0.13959999829530717,0.12367499861866235,0.1314416663100322,-0.4297992357775085,12.876490684869724,-5.908832343201258,53.56797797826076,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-12,0.0820000022649765,0.13899999856948853,0.0820000022649765,0.13899999856948853,21706,0.0,0.0,0.14149999842047692,0.12367499861866235,0.13137083301941554,-1.7667843667103607,14.412775420176802,-5.858099719605044,53.567977978260764,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-13,0.13899999856948853,0.13899999856948853,0.13899999856948853,0.13899999856948853,1000,0.0,0.0,0.14089999869465827,0.12389999870210885,0.1312666663279136,-1.3484741964314726,13.720742672017533,-5.611986524745184,53.56797797826076,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-14,0.10999999940395355,0.13500000536441803,0.10999999940395355,0.13500000536441803,57037,0.0,0.0,0.1397999994456768,0.12399999890476465,0.13114583306014538,-3.433472174743428,12.741936032634149,-5.448769502347469,51.93788804317726,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-15,0.10350000113248825,0.11299999803304672,0.10350000113248825,0.11299999803304672,92816,0.0,0.0,0.13509999960660934,0.1233499988913536,0.13092083303878704,-16.358254358189832,9.52574043037091,-5.782757389872763,44.00615649946297,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-18,0.08579999953508377,0.12999999523162842,0.08579999953508377,0.12999999523162842,161895,0.0,0.0,0.13209999948740006,0.1231249988079071,0.13086249971141417,-1.5897079969117978,7.289340723970494,-5.912695325681742,50.31977043875251,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-19,0.12449999898672104,0.12449999898672104,0.10499999672174454,0.1080000028014183,69794,0.0,0.0,0.12690000012516975,0.12234999891370535,0.1306083330263694,-14.89361489764314,3.718840418358777,-6.322976429839833,43.48620147177459,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-20,0.10499999672174454,0.13600000739097595,0.10499999672174454,0.1054999977350235,101282,0.0,0.0,0.1273499995470047,0.12208749894052744,0.13026249967515469,-17.15744160950421,4.31043362518287,-6.275789851272514,42.77530704887807,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-21,0.1054999977350235,0.13449999690055847,0.1054999977350235,0.13449999690055847,1078,0.0,0.0,0.12729999870061875,0.12244999893009663,0.13016666633387405,5.6559295156573475,3.960800173865954,-5.9282976364965645,52.479815297061464,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-22,0.1340000033378601,0.1340000033378601,0.11050000041723251,0.11949999630451202,12511,0.0,0.0,0.1262499988079071,0.12218749895691872,0.1300458329419295,-5.34653668683625,3.324808090572963,-6.042741860494553,47.95022724544954,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-25,0.1120000034570694,0.1120000034570694,0.1120000034570694,0.1120000034570694,53329,0.0,0.0,0.12354999929666519,0.12173749916255475,0.12982916633288066,-9.348438612178562,1.4888593461988473,-6.232549587185182,45.820703825590336,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-26,0.11100000143051147,0.11100000143051147,0.11100000143051147,0.11100000143051147,51120,0.0,0.0,0.12074999958276748,0.12163749914616347,0.129529166345795,-8.074532659168186,-0.7296266115513729,-6.092579318053899,45.53035670860278,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-27,0.11100000143051147,0.11100000143051147,0.11050000041723251,0.11050000041723251,140270,0.0,0.0,0.11789999976754188,0.121849999204278,0.1292666663105289,-6.276504974469563,-3.241690162109936,-5.7374939092452,45.3755348747543,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-28,0.11299999803304672,0.11299999803304672,0.11299999803304672,0.11299999803304672,242647,0.0,0.0,0.11569999903440475,0.12217499911785126,0.1290749995658795,-2.333622319698685,-5.299775019601724,-5.345729592279799,46.35771649987644,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-11-29,0.11299999803304672,0.11299999803304672,0.11299999803304672,0.11299999803304672,41506,0.0,0.0,0.11569999903440475,0.12224999908357859,0.12883333284407855,-2.333622319698685,-5.35787329102211,-5.109961541138962,46.35771649987644,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-02,0.10999999940395355,0.10999999940395355,0.10050000250339508,0.10050000250339508,120888,0.0,0.0,0.11274999976158143,0.12226249910891056,0.1285291662439704,-10.864742602297039,-7.780390075991711,-4.8756771075326455,41.98055643604347,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-03,0.10000000149011612,0.10999999940395355,0.10000000149011612,0.10999999940395355,12100,0.0,0.0,0.11294999942183495,0.12213749904185534,0.1283791661883394,-2.6117751509356086,-7.52225949613715,-4.8619003626547785,46.142666224982975,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-04,0.10999999940395355,0.10999999940395355,0.1014999970793724,0.1014999970793724,55772,0.0,0.0,0.11254999935626983,0.12179999891668558,0.12817499948044617,-9.817860808616578,-7.5944167838154035,-4.97366927216811,43.15937671509598,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-05,0.10000000149011612,0.10949999839067459,0.10000000149011612,0.10949999839067459,53855,0.0,0.0,0.11004999950528145,0.12153749894350767,0.12801249952365953,-0.4997738455968505,-9.451814903288218,-5.058100266962714,46.65513226138913,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-06,0.10050000250339508,0.10050000250339508,0.10050000250339508,0.10050000250339508,16411,0.0,0.0,0.10815000012516976,0.12104999907314777,0.12778333282719057,-7.073506808063604,-10.656752620198564,-5.269336465929172,43.419882569162276,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-09,0.12999999523162842,0.12999999523162842,0.11999999731779099,0.125,36938,0.0,0.0,0.10944999977946282,0.12167499903589488,0.12777499947696924,14.207400869684589,-10.047256505689887,-4.774017191190722,52.97883274377261,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-10,0.11999999731779099,0.12549999356269836,0.10100000351667404,0.10400000214576721,352662,0.0,0.0,0.10874999985098839,0.12177499905228614,0.12745833278944094,-4.367813987797452,-10.695955083280477,-4.45897385661208,45.831438533703434,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-11,0.10750000178813934,0.12449999898672104,0.10750000178813934,0.10849999636411667,291586,0.0,0.0,0.10854999944567681,0.12158749904483557,0.1273208327591419,-0.0460645617830373,-10.722730298409347,-4.503060174883028,47.46695643591291,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-12,0.10000000149011612,0.10849999636411667,0.10000000149011612,0.10849999636411667,44176,0.0,0.0,0.1080999992787838,0.12147499900311232,0.12714999945213398,0.37002505828080073,-11.010495850249672,-4.463232775048527,47.466956435912905,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-13,0.1080000028014183,0.1080000028014183,0.10400000214576721,0.10400000214576721,189485,0.0,0.0,0.10719999969005585,0.12124999910593033,0.12693333284308514,-2.985072344720798,-11.58762846967089,-4.4774163018161195,45.861045992203756,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-16,0.10499999672174454,0.10999999940395355,0.10499999672174454,0.10599999874830246,18059,0.0,0.0,0.10774999931454658,0.12109999898821115,0.12673333287239075,-1.6241304662429517,-11.023946973743714,-4.445029382957887,46.723757339751685,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-17,0.1014999970793724,0.1145000010728836,0.1014999970793724,0.10949999839067459,113000,0.0,0.0,0.10769999921321868,0.12083749901503324,0.12635416618237894,1.6713084406735843,-10.872038819820439,-4.366035037881511,48.27708150067663,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-18,0.1054999977350235,0.1054999977350235,0.1054999977350235,0.1054999977350235,2000,0.0,0.0,0.1080999992787838,0.12047499902546406,0.1260083328311642,-2.4051818326613006,-10.27184050365888,-4.3912443577157125,46.604701424342814,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-19,0.1054999977350235,0.1054999977350235,0.1054999977350235,0.1054999977350235,5139,0.0,0.0,0.10769999921321868,0.12043749894946813,0.12571249945710103,-2.042712622346208,-10.576024782442312,-4.196082752640657,46.604701424342814,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-20,0.10050000250339508,0.10450000315904617,0.10050000250339508,0.10450000315904617,55434,0.0,0.0,0.1080999992787838,0.12004999909549952,0.12542499949534733,-3.3302462014393206,-9.954185678260199,-4.28542987560243,46.141264727403374,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-23,0.10450000315904617,0.10450000315904617,0.10450000315904617,0.10450000315904617,80628,0.0,0.0,0.10604999959468842,0.1196624992415309,0.12514583288381498,-1.4615713734711555,-11.375744057765788,-4.381555115282816,46.141264727403374,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-27,0.10100000351667404,0.1014999970793724,0.10100000351667404,0.1014999970793724,26536,0.0,0.0,0.10579999908804893,0.11919999923557043,0.12479999947051207,-4.06427414531259,-11.241610934107122,-4.487179694471729,44.598242122771815,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2024-12-30,0.10050000250339508,0.1014999970793724,0.10050000250339508,0.1014999970793724,27372,0.0,0.0,0.1050999991595745,0.11811249926686287,0.12452083273480336,-3.4253112359555553,-11.017038999308602,-5.146394645134237,44.598242122771815,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-02,0.09099999815225601,0.10000000149011612,0.09099999815225601,0.10000000149011612,40650,0.0,0.0,0.10424999967217445,0.11696249935775996,0.12405416605373223,-4.076736878103517,-10.868868017860194,-5.7165889075427145,43.749850098119126,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-03,0.10000000149011612,0.10499999672174454,0.10000000149011612,0.10499999672174454,104965,0.0,0.0,0.10434999912977219,0.11558749936521054,0.12362916599959135,0.6229013870560677,-9.722072280439525,-6.504667866486614,47.34550946919481,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-07,0.0949999988079071,0.10000000149011612,0.0949999988079071,0.10000000149011612,286325,0.0,0.0,0.10374999940395355,0.1140874994918704,0.12311249934136867,-3.6144558413313375,-9.06102783736923,-7.3306933883890855,44.29617036654127,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-08,0.10999999940395355,0.13950000703334808,0.10999999940395355,0.13950000703334808,154814,0.0,0.0,0.1067500002682209,0.11357499975711108,0.12309166602790356,30.679163168936068,-6.0092445551274185,-7.731365232017538,64.01440019657704,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-09,0.15000000596046448,0.1599999964237213,0.15000000596046448,0.1599999964237213,225510,0.0,0.0,0.11220000013709068,0.11504999957978726,0.12320833268264929,42.60249218202013,-2.477183357762729,-6.621575769453552,69.95803788180123,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-10,0.1599999964237213,0.1599999964237213,0.11999999731779099,0.15000000596046448,26701,0.0,0.0,0.11665000095963478,0.11542499959468841,0.12329166606068612,28.589802594489505,1.061296399608339,-6.380533832777966,64.37262320555328,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-13,0.15000000596046448,0.15000000596046448,0.125,0.15000000596046448,39560,0.0,0.0,0.12120000123977662,0.11592499986290931,0.12338333278894424,23.76237988951108,4.550357026616707,-6.0448463803396555,64.37262320555328,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-14,0.125,0.1599999964237213,0.125,0.12549999356269836,58041,0.0,0.0,0.12330000028014183,0.11558749973773956,0.12330416602392992,1.7842605657405277,6.672434787413371,-6.258236469230706,52.46950260461944,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-15,0.12849999964237213,0.12849999964237213,0.12849999964237213,0.12849999964237213,48783,0.0,0.0,0.1260000005364418,0.11532499976456165,0.12325833265980085,1.984126266100508,9.256449853607972,-6.4363461066243675,53.60088607097043,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-16,0.1599999964237213,0.1599999964237213,0.13300000131130219,0.13300000131130219,66164,0.0,0.0,0.12915000095963478,0.115174999833107,0.12324999930957953,2.9810300604416637,12.13371056807301,-6.551723749863666,55.318937591201184,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-17,0.13300000131130219,0.15000000596046448,0.13300000131130219,0.15000000596046448,20933,0.0,0.0,0.1341500014066696,0.11554999984800815,0.12341666606565317,11.81513558523664,16.09692910699046,-6.374071240475936,61.16859754432438,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-20,0.15000000596046448,0.15000000596046448,0.13050000369548798,0.14900000393390656,20719,0.0,0.0,0.13855000212788582,0.11644999999552966,0.12357499947150548,7.542404652130623,18.978104021644093,-5.765728914786472,60.66546181267717,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-21,0.14900000393390656,0.14900000393390656,0.14900000393390656,0.14900000393390656,8936,0.0,0.0,0.14345000237226485,0.1169250002130866,0.1237333328773578,3.868944907535785,22.685483951967946,-5.502424048513659,60.66546181267717,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-22,0.13600000739097595,0.14900000393390656,0.13600000739097595,0.14900000393390656,7420,0.0,0.0,0.1444000020623207,0.11795000024139882,0.12382499960561594,3.18559681848243,22.424757750562772,-4.7445987344470515,60.66546181267717,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-23,0.13050000369548798,0.14900000393390656,0.13050000369548798,0.1315000057220459,130965,0.0,0.0,0.14155000299215317,0.11860000044107437,0.1237791663656632,-7.099962598138833,19.35076093231666,-4.184198420991754,51.42087915749122,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-24,0.14149999618530273,0.14149999618530273,0.1354999989271164,0.1354999989271164,50572,0.0,0.0,0.14010000228881836,0.11862500049173832,0.12375833305219809,-3.2833713679882646,18.103268036298694,-4.147868215302042,53.177220503569764,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-27,0.1354999989271164,0.1354999989271164,0.10999999940395355,0.1354999989271164,42553,0.0,0.0,0.13865000158548355,0.11902500055730343,0.12375416631499926,-2.2719095725542005,16.488133531855645,-3.8214194305655833,53.177220503569764,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-28,0.13449999690055847,0.13449999690055847,0.1289999932050705,0.12950000166893005,68772,0.0,0.0,0.1390500023961067,0.11946250051259995,0.12388333299507698,-6.868033486236063,16.39636019626161,-3.568544997617,50.0305196827755,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-29,0.12950000166893005,0.1599999964237213,0.12950000166893005,0.1599999964237213,7119,0.0,0.0,0.14220000207424163,0.12068750038743019,0.12414999958127737,12.517576715776999,17.82496250046787,-2.7889643218084634,62.25696129712022,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-30,0.1599999964237213,0.1599999964237213,0.1599999964237213,0.1599999964237213,0,0.0,0.0,0.14490000158548355,0.12192500028759241,0.12441666616747776,10.420976309879155,18.843552383595252,-2.002678545116542,62.25696129712022,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-01-31,0.15000000596046448,0.15049999952316284,0.15000000596046448,0.15000000596046448,100350,0.0,0.0,0.14490000158548355,0.12285000048577785,0.12447499949485064,3.5196717178585994,17.94871877290582,-1.3054822379332567,56.95768277635429,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-03,0.15049999952316284,0.17800000309944153,0.15049999952316284,0.15049999952316284,50020,0.0,0.0,0.1450500011444092,0.12378750052303075,0.12456249948590994,3.757323912964144,17.176613576927775,-0.622176791632908,57.15405860309543,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-04,0.17800000309944153,0.17800000309944153,0.17000000178813934,0.17000000178813934,17819,0.0,0.0,0.14715000092983246,0.12552500050514936,0.12482083284606536,15.52837289427049,17.227644164634746,0.5641427340517846,64.04404205092263,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-05,0.1784999966621399,0.2199999988079071,0.1784999966621399,0.2199999988079071,206138,0.0,0.0,0.15425000041723252,0.1282750004902482,0.12558749945213396,42.625606620957335,20.249463907785373,2.139943107266459,75.10055459783678,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-06,0.2199999988079071,0.23000000417232513,0.2199999988079071,0.23000000417232513,131984,0.0,0.0,0.16410000026226043,0.13148750066757203,0.1263374994819363,40.158442294177334,24.80273746866604,4.076383660238654,76.64723487809528,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-07,0.23000000417232513,0.23000000417232513,0.20000000298023224,0.20000000298023224,74241,0.0,0.0,0.17055000066757203,0.13375000078231097,0.12685416620224715,17.267664730217593,27.51401844487168,5.436033191901319,63.836214494861856,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-10,0.20000000298023224,0.20000000298023224,0.20000000298023224,0.20000000298023224,14669,0.0,0.0,0.1770000010728836,0.13623750079423189,0.12737916627277932,12.994351281318853,29.92017619305708,6.9543040519535735,63.836214494861856,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-11,0.20000000298023224,0.2150000035762787,0.20000000298023224,0.2150000035762787,32671,0.0,0.0,0.18555000126361848,0.13848750088363887,0.12802916634827852,15.87173382490005,33.98321153872425,8.168712515795411,67.03160812501814,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-12,0.2150000035762787,0.2150000035762787,0.2150000035762787,0.2150000035762787,39123,0.0,0.0,0.1910500019788742,0.14126250091940165,0.1286624997233351,12.535986050422974,35.24466913401113,9.793064197540483,67.03160812501814,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-13,0.19949999451637268,0.19949999451637268,0.19949999451637268,0.19949999451637268,55100,0.0,0.0,0.19500000178813934,0.14353750087320805,0.1291583330060045,2.307688557419824,35.85300050639032,11.132977278775408,60.61319456661557,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-14,0.1899999976158142,0.1899999976158142,0.1850000023841858,0.1875,173893,0.0,0.0,0.1987500011920929,0.14551250096410512,0.12955416633437078,-5.660377924335066,36.58620384864415,12.317886086771557,56.132013827906604,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-17,0.12349999696016312,0.1899999976158142,0.12349999696016312,0.1899999976158142,22726,0.0,0.0,0.20270000100135804,0.1476625008508563,0.130054166354239,-6.26541851149707,37.27249628942105,13.539231375837717,56.84778079616492,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-18,0.1315000057220459,0.1340000033378601,0.1315000057220459,0.1340000033378601,223177,0.0,0.0,0.19910000115633011,0.14836250096559525,0.13007083305468162,-32.69713583143304,34.1983316946785,14.062851356709494,40.791984224029356,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-19,0.13500000536441803,0.1354999989271164,0.13500000536441803,0.1354999989271164,137940,0.0,0.0,0.19065000116825104,0.14901250097900628,0.13019166638453802,-28.927354787931037,27.942286664332194,14.456251400053885,41.27046182286638,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-20,0.1354999989271164,0.1354999989271164,0.12999999523162842,0.12999999523162842,72020,0.0,0.0,0.18065000027418138,0.14962500091642142,0.13026666635026535,-28.037644597663412,20.735170705255413,14.86054345944859,39.99421133001906,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-21,0.12999999523162842,0.12999999523162842,0.11100000143051147,0.12800000607967377,104441,0.0,0.0,0.17345000058412552,0.15018750112503768,0.13027499970048667,-26.20351360702816,15.488971642001548,15.284975221901012,39.515674535693975,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-24,0.13950000703334808,0.13950000703334808,0.12950000166893005,0.12950000166893005,28852,0.0,0.0,0.1664000004529953,0.15081250108778477,0.1302791664376855,-22.17547997813183,10.335681228532493,15.761027040283276,40.09461128042163,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-25,0.12950000166893005,0.12950000166893005,0.10249999910593033,0.11949999630451202,42989,0.0,0.0,0.15684999972581865,0.1511875009164214,0.13019999979684752,-23.812561993367055,3.745348507696771,16.119432528664305,37.516478538787496,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-26,0.11949999630451202,0.11999999731779099,0.10999999940395355,0.11999999731779099,115519,0.0,0.0,0.14734999909996987,0.15165000092238187,0.1300833330800136,-18.561250050380547,-2.8354776104570165,16.579116887405338,37.73207369762637,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-27,0.11999999731779099,0.11999999731779099,0.11500000208616257,0.11500000208616257,41469,0.0,0.0,0.13889999985694884,0.15198750104755163,0.13004166645308335,-17.20662188293776,-8.610906226103527,16.876002279150992,36.380242437680224,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-02-28,0.11999999731779099,0.11999999731779099,0.11599999666213989,0.11949999630451202,79056,0.0,0.0,0.13209999948740006,0.15247500091791152,0.13007916640490294,-9.538231061151404,-13.362847226005803,17.21708028424484,38.51528256278119,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-03,0.10249999910593033,0.10949999839067459,0.10249999910593033,0.10949999839067459,45866,0.0,0.0,0.12404999956488609,0.15258750095963478,0.12992499967416127,-11.72914246291546,-18.7023846745468,17.44275646896961,35.651961198101034,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-04,0.10300000011920929,0.10300000011920929,0.10300000011920929,0.10300000011920929,136394,0.0,0.0,0.12094999924302101,0.1526625009253621,0.12977499968061845,-14.84084269214864,-20.772947835988607,17.63629458760988,33.88841717539036,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-05,0.10400000214576721,0.10949999839067459,0.10199999809265137,0.10300000011920929,21099,0.0,0.0,0.1176999993622303,0.15175000075250863,0.12968333301444848,-12.48937920363168,-22.438221562720777,17.015808604797062,33.88841717539036,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-06,0.11749999970197678,0.11749999970197678,0.1145000010728836,0.1145000010728836,18147,0.0,0.0,0.11614999994635582,0.1506125008687377,0.12975416636715334,-1.4205758710583447,-22.881567415454285,16.075271481120282,39.98028931766439,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-07,0.10999999940395355,0.10999999940395355,0.10400000214576721,0.10499999672174454,24305,0.0,0.0,0.11384999901056289,0.1494875006377697,0.1294458329677582,-7.773388112192483,-23.83978692209306,15.482667313828014,36.95119804531626,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-10,0.10499999672174454,0.10499999672174454,0.0997999981045723,0.10000000149011612,56371,0.0,0.0,0.1108999989926815,0.14823750052601098,0.12927083298563957,-9.828672318820036,-25.18762216095105,14.672039393819311,35.42972360560019,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-11,0.09019999951124191,0.10499999672174454,0.09019999951124191,0.10000000149011612,419387,0.0,0.0,0.10894999951124192,0.14760000072419643,0.12895416636019946,-8.214775641373269,-26.185637549674162,14.459272538674517,35.42972360560019,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-12,0.10000000149011612,0.14000000059604645,0.10000000149011612,0.1289999932050705,109375,0.0,0.0,0.10984999909996987,0.1476125005632639,0.12887083298216265,17.432857771508058,-25.582183974391608,14.54298629674825,49.434800872255444,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-13,0.11999999731779099,0.11999999731779099,0.10300000011920929,0.1145000010728836,38924,0.0,0.0,0.10979999899864197,0.14715000055730343,0.12874166636417309,4.280511946361462,-25.382263960044327,14.298660808893423,44.26506296274958,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-14,0.1340000033378601,0.1340000033378601,0.11900000274181366,0.11900000274181366,84827,0.0,0.0,0.10974999964237213,0.14637500047683716,0.12864166640987,8.428248865223962,-25.021349762701238,13.785062462162406,46.147293702312446,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-17,0.1145000010728836,0.1145000010728836,0.10249999910593033,0.10300000011920929,48621,0.0,0.0,0.1090999998152256,0.14522500038146974,0.12834166642278433,-5.591200464113122,-24.87519398956984,13.154990447972034,40.86320784051422,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-18,0.10300000011920929,0.10499999672174454,0.10300000011920929,0.10300000011920929,142262,0.0,0.0,0.1090999998152256,0.1440750002861023,0.12804166643569867,-5.591200464113122,-24.27555120695734,12.521965932437634,40.86320784051422,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-19,0.10100000351667404,0.1379999965429306,0.10100000351667404,0.13750000298023224,20181,0.0,0.0,0.1125500001013279,0.14378750026226045,0.12802916647245485,22.1679279044354,-21.724767524268156,12.308393644971485,54.02732756217865,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-20,0.13750000298023224,0.13750000298023224,0.13750000298023224,0.13750000298023224,200073,0.0,0.0,0.11485000029206276,0.1439375001937151,0.1282083331917723,19.72137799788479,-20.208423699526232,12.268443563972802,54.02732756217865,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-21,0.13750000298023224,0.13750000298023224,0.10899999737739563,0.13750000298023224,17718,0.0,0.0,0.11810000091791154,0.14398750029504298,0.12835416657229265,16.426758604180858,-17.978990762452085,12.179841247261109,54.02732756217865,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-24,0.1054999977350235,0.12999999523162842,0.1054999977350235,0.12999999523162842,24359,0.0,0.0,0.12110000029206276,0.1438500002026558,0.12835416657229265,7.349293904294885,-15.81508507371765,12.072715708558983,50.94798701144314,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-25,0.10700000077486038,0.10999999940395355,0.10700000077486038,0.10999999940395355,93796,0.0,0.0,0.1221000000834465,0.14336250014603139,0.12818749994039536,-9.909910459642484,-14.831284360224295,11.838127908487259,43.78176331937826,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-26,0.10999999940395355,0.10999999940395355,0.1054999977350235,0.1054999977350235,3270,0.0,0.0,0.1197500005364418,0.14200000017881392,0.1281083332374692,-11.899793517814478,-15.66901381292517,10.843687206197822,42.33875489594499,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-27,0.10949999839067459,0.10949999839067459,0.10599999874830246,0.10599999874830246,23098,0.0,0.0,0.11890000030398369,0.14065000023692847,0.1281416665762663,-10.849454602775996,-15.463917452048603,9.761332121599626,42.56526788453481,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-28,0.10999999940395355,0.10999999940395355,0.10499999672174454,0.10499999672174454,72904,0.0,0.0,0.11749999970197678,0.13952500000596046,0.12818333320319653,-10.638300435690931,-15.785701704384724,8.848004275864087,42.208143077140875,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-03-31,0.10100000351667404,0.10100000351667404,0.10100000351667404,0.10100000351667404,4784,0.0,0.0,0.11730000004172325,0.13828750010579824,0.1281083332374692,-13.895990212490494,-15.1767152114387,7.9457492038869395,40.73588200529369,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-01,0.13750000298023224,0.13750000298023224,0.10249999910593033,0.10249999910593033,187897,0.0,0.0,0.11724999994039535,0.136600000038743,0.12812916655093431,-12.579958074169095,-14.16544662727638,6.61116724305027,41.55911128111954,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-02,0.10249999910593033,0.10649999976158142,0.07500000298023224,0.07500000298023224,230634,0.0,0.0,0.11099999994039536,0.13297500014305114,0.12779583322505156,-32.43242971125618,-16.52566285317964,4.052688407202557,32.61440999598268,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-03,0.07500000298023224,0.07500000298023224,0.03579999879002571,0.038600001484155655,760946,0.0,0.0,0.10110999979078769,0.1281900000758469,0.12715916655336817,-61.823754758159374,-21.12489294721635,0.8106639500866021,24.957492180604646,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-04,0.03920000046491623,0.05999999865889549,0.03920000046491623,0.05999999865889549,239890,0.0,0.0,0.09335999935865402,0.12468999996781349,0.12665916656454404,-35.73264880990621,-25.126313751902117,-1.5546972636418572,34.6684957746923,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-07,0.05999999865889549,0.05999999865889549,0.049800001084804535,0.049800001084804535,622649,0.0,0.0,0.08533999994397164,0.1209349999204278,0.12607416659593582,-41.64518266053459,-29.43316657698498,-4.076304301085643,32.50909761886315,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-08,0.04879999905824661,0.04879999905824661,0.04780000075697899,0.04800000041723251,290229,0.0,0.0,0.07914000004529953,0.11675999984145165,0.1256408332536618,-39.347990409707556,-32.2199382042106,-7.068429253633046,32.128777578309794,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-09,0.05000000074505806,0.05000000074505806,0.04740000143647194,0.04740000143647194,385864,0.0,0.0,0.07333000041544438,0.11256999978795648,0.12520249991988142,-35.360696620848785,-34.858309892890546,-10.089654871115691,31.99441417720152,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-10,0.04740000143647194,0.04740000143647194,0.036400001496076584,0.03999999910593033,173127,0.0,0.0,0.06673000045120717,0.10858249990269542,0.12456916660691301,-40.05694764654131,-38.54442427554508,-12.833566395017057,30.31077194601464,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-11,0.03999999910593033,0.043800000101327896,0.033799998462200165,0.033799998462200165,169378,0.0,0.0,0.05961000062525272,0.10473999986425042,0.12390916661048929,-43.2981075194262,-43.08764492790624,-15.470337885894663,28.936821604182725,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-14,0.033799998462200165,0.03799999877810478,0.033799998462200165,0.03799999877810478,199520,0.0,0.0,0.053310000151395795,0.10093999989330768,0.12328416661669811,-28.718816975824296,-47.186447188682585,-18.124117100017,31.211561590074652,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-15,0.03799999877810478,0.052000001072883606,0.030400000512599945,0.03220000118017197,126127,0.0,0.0,0.04628000035881996,0.09839499983936548,0.12261916659772396,-30.423507064568668,-52.965089248057055,-19.75561197364077,29.793260795959668,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-16,0.05180000141263008,0.05180000141263008,0.05180000141263008,0.05180000141263008,14108,0.0,0.0,0.04396000020205974,0.09630249990150333,0.12205083329851428,17.83439757628344,-54.352171286289206,-21.096401147901368,39.75601638148003,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-17,0.05180000141263008,0.05180000141263008,0.05180000141263008,0.05180000141263008,25501,0.0,0.0,0.04528000019490719,0.09434750005602836,0.12148249999930462,14.399295913554836,-52.00720722009845,-22.336550485404548,39.75601638148003,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-22,0.05180000141263008,0.05180000141263008,0.04899999871850014,0.04899999871850014,26042,0.0,0.0,0.04418000020086765,0.09237249987199903,0.12099916664883495,10.909910583336359,-52.17191235260703,-23.65856523616938,38.8427809995363,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-23,0.03999999910593033,0.03999999910593033,0.03460000082850456,0.03460000082850456,918564,0.0,0.0,0.042660000175237654,0.08999999985098839,0.12028750001142423,-18.89357551248109,-52.599999726812044,-25.17925815862771,34.458799846235834,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-24,0.03460000082850456,0.03460000082850456,0.032600000500679016,0.03460000082850456,166002,0.0,0.0,0.04132000021636486,0.0878774999640882,0.11957583337401351,-16.26330917878076,-52.98000030354688,-26.508979712295332,34.458799846235834,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-25,0.04820000007748604,0.04820000007748604,0.03500000014901161,0.03999999910593033,443076,0.0,0.0,0.0405799999833107,0.08587750000879169,0.118909166722248,-1.4292776678632584,-52.74664495454998,-27.778906895052742,37.52543535582291,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-28,0.03999999910593033,0.04780000075697899,0.03999999910593033,0.046799998730421066,510124,0.0,0.0,0.041259999945759775,0.08417249992489814,0.11809083341310421,13.427045060456013,-50.98161515628799,-28.722240759833817,41.25306643368158,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-29,0.046799998730421066,0.046799998730421066,0.046799998730421066,0.046799998730421066,11683,0.0,0.0,0.04255999997258186,0.08235499998554588,0.11726416675373912,9.962403102844709,-48.321291991923296,-29.769679634107078,41.25306643368158,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-04-30,0.03819999843835831,0.03819999843835831,0.03819999843835831,0.03819999843835831,240000,0.0,0.0,0.04257999993860721,0.08057249998673796,0.11624916677052775,-10.286523030916133,-47.1531850872,-30.689825806850234,37.93328787007459,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-02,0.04780000075697899,0.04780000075697899,0.04019999876618385,0.047600001096725464,116384,0.0,0.0,0.04411999993026257,0.07918750001117587,0.1153125001428028,7.887581985411361,-44.284135849678506,-31.327913354484366,43.30386013878414,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-05,0.047600001096725464,0.047600001096725464,0.047600001096725464,0.047600001096725464,22730,0.0,0.0,0.043699999898672105,0.07780250003561377,0.11437583351507782,8.924487888092344,-43.83213922602923,-31.97645197894247,43.30386013878414,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-06,0.047600001096725464,0.047600001096725464,0.047600001096725464,0.047600001096725464,0,0.0,0.0,0.04327999986708164,0.07613000003620982,0.1139308334949116,9.98151858343598,-43.14987541508431,-33.17875617963424,43.30386013878413,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-07,0.04500000178813934,0.049800001084804535,0.03999999910593033,0.03999999910593033,60000,0.0,0.0,0.04237999990582466,0.07450500009581447,0.11313916677609086,-5.615858436014831,-43.117911749112956,-34.14747322360584,39.82411277997445,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-08,0.039400000125169754,0.03999999910593033,0.039400000125169754,0.03999999910593033,88000,0.0,0.0,0.042919999733567235,0.07300500003620983,0.11238916680837671,-6.80335658379142,-41.20950659231655,-35.04267171881148,39.82411277997445,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-09,0.049800001084804535,0.049800001084804535,0.049800001084804535,0.049800001084804535,4000,0.0,0.0,0.044439999759197234,0.07175000002607704,0.11164583349600435,12.061209168881698,-38.062718128159126,-35.734278853635075,46.279774347570466,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-12,0.04960000142455101,0.04960000142455101,0.03819999843835831,0.039000000804662704,261073,0.0,0.0,0.04433999992907047,0.06950000021606684,0.11081250018129746,-12.04329980367619,-36.20143914931951,-37.281443788056684,41.05287522267591,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-13,0.039000000804662704,0.049800001084804535,0.03739999979734421,0.0430000014603138,566709,0.0,0.0,0.04396000020205974,0.06771250022575259,0.11001250020538768,-2.183800585380719,-35.078456628395536,-38.450176026054464,43.593849825925275,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-14,0.03880000114440918,0.03999999910593033,0.03880000114440918,0.03999999910593033,180757,0.0,0.0,0.04328000023961067,0.0657375001348555,0.10922083348656694,-7.578560802960495,-34.16238805731124,-39.81230683160777,42.12713448901214,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-15,0.041999999433755875,0.041999999433755875,0.03799999877810478,0.041999999433755875,25600,0.0,0.0,0.04366000033915043,0.06421250011771917,0.10862916683157285,-3.8021092361421966,-32.007007577793054,-40.88834335139544,43.49210384839318,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-16,0.03819999843835831,0.041999999433755875,0.03819999843835831,0.041999999433755875,60000,0.0,0.0,0.04310000017285347,0.06268750010058284,0.10789583353325724,-2.5522058809420325,-31.24626105092881,-41.89998070568649,43.49210384839318,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-19,0.041999999433755875,0.041999999433755875,0.03539999946951866,0.035999998450279236,119992,0.0,0.0,0.04193999990820885,0.060149999987334016,0.10729583349699776,-14.16309363598016,-30.27431435238522,-43.94004126076613,40.19375126798997,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-20,0.03519999980926514,0.04100000113248825,0.03519999980926514,0.04100000113248825,10588,0.0,0.0,0.041279999911785124,0.05773749994114041,0.10675833352530996,-0.6782916179632454,-28.50400527583049,-45.9175709899479,44.00477172759304,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-21,0.04100000113248825,0.04100000113248825,0.04100000113248825,0.04100000113248825,1284,0.0,0.0,0.041380000114440915,0.05532499989494681,0.10597916689390938,-0.9183155652531071,-25.20560290462754,-47.79634383205711,44.00477172759303,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-22,0.03200000151991844,0.03200000151991844,0.03200000151991844,0.03200000151991844,17000,0.0,0.0,0.04058000035583973,0.052875000052154064,0.10525000027070443,-21.143417350134573,-23.252954485459995,-49.762470388447646,38.83827382811623,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-23,0.03519999980926514,0.04179999977350235,0.03519999980926514,0.035999998450279236,123579,0.0,0.0,0.0392000000923872,0.05102500002831221,0.10461666689564784,-8.163269475934053,-23.17491411928207,-51.22670073286869,42.09239654808368,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-26,0.20000000298023224,0.20000000298023224,0.04100000113248825,0.05400000140070915,1389738,0.0,0.0,0.04070000015199184,0.04973750011995435,0.10414166689539948,32.67813562419953,-18.170394463264795,-52.24053771876823,53.96269605486327,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-27,0.05480000004172325,0.05480000004172325,0.04960000142455101,0.04960000142455101,363424,0.0,0.0,0.041360000148415565,0.048327500186860564,0.10363416690379382,19.922633574872233,-14.41725727899194,-53.367213120240365,51.199832686561535,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-28,0.04520000144839287,0.04520000144839287,0.03200000151991844,0.03200000151991844,891921,0.0,0.0,0.040560000389814374,0.04650250030681491,0.10295916693285108,-21.10453350006762,-12.778882592963859,-54.83403596578887,41.948105898077664,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-05-30,0.035999998450279236,0.03959999978542328,0.035999998450279236,0.03959999978542328,544593,0.0,0.0,0.040320000424981114,0.04496750021353364,0.10234750028078755,-1.7857158530974222,-10.335241600007361,-56.06389986060574,46.448125884134335,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-02,0.03959999978542328,0.03999999910593033,0.03959999978542328,0.03999999910593033,305033,0.0,0.0,0.04012000039219856,0.04340500021353364,0.10184333358580867,-0.2991058950527015,-7.568252056616324,-57.38061718397846,46.68238645353489,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-03,0.03999999910593033,0.04320000112056732,0.038600001484155655,0.038600001484155655,615155,0.0,0.0,0.040380000695586206,0.042495000176131725,0.1012483336031437,-4.408120804280017,-4.977054881231549,-58.028938685848864,45.925156314409826,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-04,0.038600001484155655,0.044599998742341995,0.038600001484155655,0.03999999910593033,239547,0.0,0.0,0.040280000492930415,0.04253000011667609,0.10073583362003168,-0.6951374964586459,-5.290382359682728,-57.780663952118374,46.853553377694155,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-05,0.052000001072883606,0.05480000004172325,0.05139999836683273,0.05139999836683273,1408994,0.0,0.0,0.04132000021636486,0.04231500010937452,0.10025166695316633,24.39496151424431,-2.351411769910947,-57.791225427560775,53.80806795212892,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-09,0.04780000075697899,0.04780000075697899,0.04780000075697899,0.04780000075697899,36196,0.0,0.0,0.042900000140070914,0.04226500010117888,0.09981250027194619,11.421912822632395,1.5024252629170591,-57.65560427198506,51.51554870092367,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-10,0.03959999978542328,0.03999999910593033,0.03759999945759773,0.03999999910593033,208581,0.0,0.0,0.04330000020563603,0.04206500006839633,0.09910416693116228,-7.621249616705922,2.9359328069217363,-57.554761448512394,46.85732588205635,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-11,0.03739999979734421,0.04820000007748604,0.03359999880194664,0.04800000041723251,220500,0.0,0.0,0.04270000010728836,0.042080000042915344,0.09863750025009116,12.412178680626065,1.4733841818933187,-57.33874040175054,51.6830398683343,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-12,0.03840000182390213,0.054999999701976776,0.03840000182390213,0.05480000004172325,19727,0.0,0.0,0.043219999969005586,0.04245000006631017,0.09819000028073788,26.793151506298113,1.813898472302991,-56.767491653997205,55.39107188977089,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-13,0.054999999701976776,0.054999999701976776,0.03840000182390213,0.03999999910593033,56020,0.0,0.0,0.04401999972760677,0.04260500008240342,0.097619166970253,-9.13221409939113,3.3212055919881753,-56.35590693435621,46.946384750351626,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-16,0.049800001084804535,0.049800001084804535,0.04039999842643738,0.04919999837875366,74173,0.0,0.0,0.04497999958693981,0.042885000072419646,0.09716250027219454,9.381944932340891,4.885156840345924,-55.8626013613482,51.85958390270906,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-17,0.03999999910593033,0.04919999837875366,0.03999999910593033,0.04919999837875366,115179,0.0,0.0,0.04589999951422215,0.043310000002384184,0.09668916693578164,7.189540085962326,5.980142026542105,-55.20697780843481,51.859583902709076,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-18,0.04919999837875366,0.05000000074505806,0.03999999910593033,0.05000000074505806,820553,0.0,0.0,0.04703999944031238,0.043264999985694885,0.09619333362206817,6.292519855365926,8.725296326974833,-55.022870757678724,52.30502964607419,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-19,0.04019999876618385,0.05000000074505806,0.04019999876618385,0.05000000074505806,210435,0.0,0.0,0.048039999604225156,0.043219999969005586,0.09573083364715179,4.079935797211206,11.152243495317313,-54.852581637064354,52.30502964607419,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-23,0.04780000075697899,0.04780000075697899,0.04780000075697899,0.04780000075697899,100000,0.0,0.0,0.047679999843239784,0.043190000019967555,0.09525000033900141,0.25167976957579313,10.395924568641856,-54.65616811942118,50.805696451399974,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-24,0.04780000075697899,0.04780000075697899,0.04780000075697899,0.04780000075697899,100927,0.0,0.0,0.047679999843239784,0.04352000001817942,0.09477750031898419,0.25167976957579313,9.558823123443535,-54.08192886317108,50.805696451399974,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-25,0.05660000070929527,0.05660000070929527,0.04520000144839287,0.04520000144839287,196462,0.0,0.0,0.04820000007748604,0.04378500003367662,0.09428333363806209,-6.224063535830685,10.08336197422332,-53.560191028289374,48.885036128169055,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
2025-06-26,0.05660000070929527,0.05660000070929527,0.0560000017285347,0.05640000104904175,150519,0.0,0.0,0.049040000140666964,0.04419500008225441,0.09390750033780933,15.008158416115952,10.962778706630129,-52.93773135982357,56.51178125733057,,,0.0,0.0,-1.0791,,2.35,-0.1128,LIDDS AB (publ),Healthcare,"LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden."
